<PAGE>
Rule 424(b)(1)
Registration No. 333-1135
3,030,000 Shares
[LOGO OF RESPIRONICS, INC.]
Common Stock
------------
Of the 3,030,000 shares of Common Stock offered hereby, 2,000,000 shares are
being sold by Respironics, Inc. ("Respironics" or the "Company") and 1,030,000
shares are being sold by the Selling Stockholders. See "Principal and Selling
Stockholders." The Company will not receive any of the proceeds from the
shares sold by the Selling Stockholders. The Common Stock is traded on the
Nasdaq National Market under the symbol "RESP." On March 25, 1996, the last
reported sale price of the Common Stock was $21.00 per share. See "Price Range
of Common Stock."
------------
FOR A DISCUSSION OF CERTAIN FACTORS WHICH SHOULD BE CONSIDERED BY POTENTIAL
INVESTORS, SEE "RISK FACTORS" BEGINNING ON PAGE 7.
------------
THESE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND
EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION NOR HAS THE
SECURITIES AND EXCHANGE COMMISSION OR ANY STATE SECURITIES COMMISSION
PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS. ANY
REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.
===============================================================================
<TABLE>
<CAPTION>
PRICE UNDERWRITING PROCEEDS PROCEEDS TO
TO DISCOUNTS AND TO SELLING
PUBLIC COMMISSIONS COMPANY(1) STOCKHOLDERS
<C> <C> <C> <C> <C>
- -------------------------------------------------------------------------------------------
Per Share.................. $21.00 $1.10 $19.90 $19.90
- -------------------------------------------------------------------------------------------
Total(2)................... $63,630,000 $3,340,575 $39,795,000 $20,494,425
</TABLE>
===============================================================================
(1) Before deducting expenses of the offering estimated at $400,000 payable by
the Company.
(2) The Company and two Selling Stockholders have granted the Underwriters a
30-day option to purchase up to 454,500 additional shares of Common Stock
solely to cover over-allotments, if any. To the extent that the option is
exercised, the Underwriters will offer the additional shares at the Price
to Public shown above. If the option is exercised in full, the total Price
to Public, Underwriting Discounts and Commissions, Proceeds to Company and
Proceeds to Selling Stockholders will be $73,174,500, $3,841,661,
$47,228,487 and $22,104,352, respectively. See "Underwriting."
------------
The shares of Common Stock are offered by the several Underwriters, subject
to prior sale, when, as and if delivered to and accepted by them, and subject
to the right of the Underwriters to reject any order in whole or in part. It
is expected that delivery of the shares of Common Stock will be made at the
offices of Alex. Brown & Sons Incorporated, Baltimore, Maryland, on or about
March 29, 1996.
Alex. Brown & Sons
INCORPORATED
Cowen & Company
Parker/Hunter
INCORPORATED
THE DATE OF THIS PROSPECTUS IS MARCH 25, 1996.
<PAGE>
OBSTRUCTIVE SLEEP APNEA
Over 18 million people in the United States have symptoms which are consistent
with a diagnosis of some degree of obstructive sleep apnea (OSA). Respironics
offers a broad array of products for OSA therapy and diagnosis.
[PHOTO] [PHOTO] [PHOTO]
REMstar Choice Aria CPAP System Cricket Oximeter and
CPAP System HMS 5000 Monitor
NON-INVASIVE VENTILATORY SUPPORT
Non-invasive ventilatory support is an emerging segment of the total
ventilation market. Respironics introduced the first non-invasive bi-level
ventilatory support system that compensates for mask leaks.
[PHOTO] [PHOTO]
BiPAP S/T BiPAP Hospital
Ventilatory Support Ventilatory Support
System System
PATIENT MASKS AND
RESUSCITATION
Respironics manufactures a variety of patient masks and resuscitation products
designed to enhance patient comfort and compliance in the OSA and ventilatory
support markets and to provide respiratory therapy in hospital and emergency
settings.
[PHOTO] [PHOTO]
GEL Mask BagEasy Disposable
Manual Resuscitator
[LOGO OF RESPIRONICS INC.]
RESPIRONICS INC.
Respironics' mission is to be first and best at solving problems in the
cardio-pulmonary marketplace by providing its worldwide customers with the
highest quality products and services.
<PAGE>
AVAILABLE INFORMATION
The Company is subject to the informational requirements of the Securities
Exchange Act of 1934, as amended (the "Exchange Act"), and in accordance
therewith files reports, proxy statements and other information with the
Securities and Exchange Commission (the "Commission"). Such reports, proxy
statements and other information may be inspected and copied at the public
reference facilities of the Commission at Room 1024, 450 Fifth Street, N.W.,
Washington, D.C. 20549; and at the Commission's regional office at Citicorp
Center, 500 West Madison Street, Suite 1400, Chicago, Illinois 60661 and Seven
World Trade Center, Suite 1300, New York, New York 10048. Copies of such
material can be obtained from the Public Reference Section of the Commission
at 450 Fifth Street, N.W., Washington, D.C. 20549 at prescribed rates.
Reports, proxy statements and other information concerning the Company may be
inspected at the National Association of Securities Dealers, Inc. at 1735 K
Street, N.W., Washington, DC 20006.
ADDITIONAL INFORMATION
The Company has filed with the Commission a Registration Statement on Form
S-3 (together with all amendments and exhibits, the "Registration Statement")
under the Securities Act of 1933, as amended (the "Securities Act"), with
respect to the Common Stock to which this Prospectus relates. This Prospectus
does not contain all the information set forth in the Registration Statement,
certain portions of which have been omitted as permitted by the rules and
regulations of the Commission. For further information with respect to the
Company and the Common Stock, reference is made to the Registration Statement.
The Registration Statement may be inspected by anyone without charge at the
principal office of the Commission in Washington, D.C., and copies of all or
part of it may be obtained from the Commission upon payment of the prescribed
fees.
Except as otherwise specified, all information in this Prospectus assumes no
exercise of the Underwriters' over-allotment option. The Company's fiscal year
ends on June 30 of each year. Unless the context indicates otherwise,
reference in this Prospectus to "fiscal year" refers to the twelve-month
period ending on June 30 of the year indicated. On each of March 9, 1992 and
March 17, 1995 the Company effected a two-for-one stock split in the form of a
stock distribution of one additional share of Common Stock for each share held
of record on February 24, 1992 and March 3, 1995, respectively. All references
to number of shares of Common Stock, and all information with respect thereto
(including per share information in the financial information herein) have
been adjusted to reflect the stock splits on a retroactive basis. See
"Underwriting." Respironics(R), REMstar(R), BiPAP(R), BagEasy(R), Circle
Seal(R) and SealEasy(R) are registered trademarks of the Company. Great
Performers(TM), Monarch Mini Mask(TM), GEL Mask(TM), Cricket(TM), Aria(TM),
Virtuoso(TM), Vitalog(TM) and HMS 5000(TM) are trademarks of the Company.
This Prospectus contains forward-looking statements which involve risks and
uncertainties. The Company's actual results may differ significantly from the
results discussed in the forward-looking statements. Factors that might cause
such a difference include, but are not limited to, those discussed in "Risk
Factors."
IN CONNECTION WITH THE OFFERING, THE UNDERWRITERS MAY OVER-ALLOT OR EFFECT
TRANSACTIONS WHICH STABILIZE OR MAINTAIN THE MARKET PRICE OF THE COMPANY'S
COMMON STOCK AT A LEVEL ABOVE THAT WHICH MIGHT OTHERWISE PREVAIL IN THE OPEN
MARKET. SUCH STABILIZING, IF COMMENCED, MAY BE DISCONTINUED AT ANY TIME.
IN CONNECTION WITH THIS OFFERING, CERTAIN UNDERWRITERS AND OTHER SELLING
GROUP MEMBERS MAY ENGAGE IN PASSIVE MARKET MAKING TRANSACTIONS IN THE
COMPANY'S COMMON STOCK ON THE NASDAQ NATIONAL MARKET IN ACCORDANCE WITH RULE
10B-6A UNDER THE SECURITIES EXCHANGE ACT OF 1934. SEE "UNDERWRITING."
2
<PAGE>
PROSPECTUS SUMMARY
The following summary is qualified in its entirety by the more detailed
information, including "Risk Factors" and "Consolidated Financial Statements"
(including the notes thereto), appearing elsewhere in this Prospectus.
THE COMPANY
Respironics is a leading developer, manufacturer and marketer of medical
devices used for the treatment of patients suffering from respiratory
disorders. The Company's products are designed to reduce costs while improving
the effectiveness of patient care and are used primarily in the home and
hospitals, as well as emergency medical settings and alternative care
facilities. The Company's primary product lines are: (i) continuous positive
airway pressure ("CPAP") devices and bi-level positive airway pressure
("BiPAP") devices for the treatment of obstructive sleep apnea ("OSA"), a
serious disorder characterized by the repeated cessation of breathing during
sleep; (ii) bi-level non-invasive ventilatory support devices; (iii) patient
mask products; and (iv) single-use resuscitation products. Respironics markets
its products through a sales organization consisting of approximately 90 direct
and independent sales representatives, who sell to a network of over 2,500
medical product dealers. The Company's sales have grown from $36.0 million in
fiscal year 1991 to $99.5 million in fiscal year 1995 and are currently
comprised of 68% equipment and 32% consumable and single-use products. With
approximately 85% of its sales currently reaching the home care market,
Respironics believes that it is well-positioned to take advantage of the
growing preference for in-home treatment of patients suffering from respiratory
disorders.
The Company believes it is the U.S. market share leader for both of its
primary product lines, OSA treatment devices and non-invasive ventilatory
support products. Devices for the treatment of OSA are estimated to constitute
a $100 million annual U.S. market that is growing at 20 to 25% per year. Growth
in the OSA market stems from several factors, including recognition of the
serious medical implications of OSA and increasing diagnosis and treatment of
the disorder. In a comprehensive study published in the April 1993 New England
Journal of Medicine, OSA was estimated to affect 4% of men and 2% of women in
the middle-aged work force, and the Company believes that the majority of these
cases remain undiagnosed. The total U.S. ventilator market is estimated to be
$250 million annually. Non-invasive ventilatory support is an emerging sector
of this market, consisting primarily of products for individuals who require
ventilatory assistance but who are not dependent on a ventilator for continuous
life support. Respironics believes that its non-invasive ventilatory support
product line represents a technological advance over traditional mechanical
ventilators, which generally require intubation of patients and thus have the
potential for adverse side effects such as infection.
Respironics is a market-driven company that has established a record of
innovation in respiratory care. In 1981, the Company introduced the first
commercially available single-use air-filled cushion anesthesia mask as a cost-
effective alternative to reusable anesthesia masks. In 1985, the Company
introduced the first commercially available CPAP product designed to treat OSA,
affording patients an alternative to surgery. In 1989, the Company introduced
the BiPAP Ventilatory Support System, a non-invasive bi-level pressure support
device. In March 1995, the Company introduced a new version of its BagEasy
manual resuscitator. The Company recently began introducing its next-generation
family of OSA products, called the "Great Performers" product line, with the
first international shipments commencing in July 1995. In February 1996, the
Company received clearance from the U.S. Food and Drug Administration (the
"FDA") to market a new product in this line, the Aria CPAP system, and expects
to begin domestic shipments of this device in spring 1996. This new family of
products also includes Virtuoso, a CPAP device that utilizes
3
<PAGE>
innovative technology to monitor the patient's airway and to continuously
adjust output automatically in order to deliver the appropriate pressure. The
Company currently is developing its next-generation family of ventilatory
support devices which it expects to introduce in international markets in
summer 1996.
In fiscal year 1995, the Company completed the acquisition of Vitalog
Monitoring, Inc. ("Vitalog"), a developer, manufacturer and marketer of
monitoring and diagnostic devices for sleep disorders. The Vitalog acquisition
is part of a strategic effort by Respironics to use the market for devices
related to the diagnosis and monitoring of sleep and other respiratory-related
disorders to drive the therapeutic markets for these disorders.
Respironics' objective is to be the market leader in innovative devices for
the treatment of respiratory disorders. The Company's strategy is to: (i)
continue to commit significant resources to the development of innovative
products; (ii) expand the breadth of its product lines to address the full
range of respiratory disorders; (iii) expand its international distribution and
manufacturing capabilities; (iv) pursue acquisitions of complementary
technologies, products and businesses; (v) enhance operational quality and
efficiency through process excellence; and (vi) develop partnering
relationships with customers.
Respironics is a Delaware corporation. The Company's executive offices are
located at 1001 Murry Ridge Drive, Murrysville, Pennsylvania 15668. The
Company's telephone number is (412) 733-0200.
THE OFFERING
<TABLE>
<S> <C>
Common Stock offered by the Company.............. 2,000,000 shares
Common Stock offered by the Selling Stockholders. 1,030,000 shares
Common Stock outstanding after the offering (1).. 18,851,860 shares
Use of Proceeds.................................. Provide working capital for
general corporate purposes,
including the acquisition of
similar or related
businesses and the
acquisition of marketing,
manufacturing or other
rights associated with
products or technologies
which would complement the
Company's products.
Nasdaq National Market Symbol.................... RESP
</TABLE>
- --------
(1) Does not include 1,546,626 shares of Common Stock reserved for issuance
pursuant to outstanding options granted at a weighted average price per
share of $5.90.
4
<PAGE>
SUMMARY FINANCIAL DATA
(AMOUNTS IN THOUSANDS EXCEPT PER SHARE AND OTHER STATISTICAL DATA)
<TABLE>
<CAPTION>
SIX MONTHS ENDED
YEAR ENDED JUNE 30 DECEMBER 31
---------------------------------------------- ---------------------
1991 1992 1993 1994 1995 1994 1995
------- ------- ------- ------- ------- -------- --------
(UNAUDITED)
INCOME STATEMENT DATA:
<S> <C> <C> <C> <C> <C> <C> <C>
Net sales.............. $36,031 $48,976 $69,286 $78,171 $99,450 $45,538 $56,916
Nonrecurring charges... -0- -0- -0- 7,086(1) -0- -0- -0-
Income before income
taxes................... 5,553 8,059 11,096 6,816 18,535 8,121 11,030
Net income............. 3,771 5,363 7,379 4,741(1) 11,677 5,116 6,728
Earnings per share..... $ 0.26 $ 0.31 $ 0.43 $ 0.27(1) $ 0.67 $ 0.29 $ 0.38
Weighted average shares
of Common Stock
outstanding and
equivalents............ 14,631 17,057 17,319 17,281 17,532 17,346 17,730
OTHER STATISTICAL DATA:
Sales growth versus
prior period............ 57% 36% 41% 13%(2) 27%(2) 24%(2) 25%
Sales by product line:
Obstructive Sleep
Apnea................... 55% 55% 57% 64% 67% 68% 68%
Non-invasive
Ventilatory Support..... 18 20 23 27 26 26 26
Patient Masks......... 22 22 18 16 15 15 16
Resuscitation......... 14 13 11 4 2 2 2
Product Line (9) (10) (9) (11) (10) (11) (12)
Transfers (3)........... ---- ---- ---- ---- ---- ---- ----
100% 100% 100% 100% 100% 100% 100%
=== === === === === === ===
International sales as
a percentage
of net sales.......... 14% 19% 18% 20% 20% 20% 23%
Gross margin........... 51% 52% 54% 55% 57% 57% 56%
Selling, general and
administrative
expenses as a
percentage of net
sales................. 31% 32% 33% 32% 32% 33% 31%
Research and
development expenses
as a percentage of net
sales.................. 5% 5% 5% 6% 7% 7% 7%
Net margin excluding
the impact of
nonrecurring charges.. 10% 11% 11% 12%(4) 12% 11% 12%
Earnings per share
growth versus prior
year excluding the
impact of nonrecurring
charges................ 73% 19% 39% 21%(5) 29%(5) 16%(5) 31%
</TABLE>
<TABLE>
<CAPTION>
DECEMBER 31, 1995
-----------------------
ACTUAL AS ADJUSTED (6)
------- ---------------
(UNAUDITED)
BALANCE SHEET DATA:
<S> <C> <C>
Working capital........................................ $44,146 $ 83,541
Total assets........................................... 83,952 123,347
Total long-term obligations............................ 5,242 5,242
Total shareholders' equity............................. 65,550 104,945
</TABLE>
- --------
(1) In the first quarter of fiscal year 1994 and the fourth quarter of fiscal
year 1994, the Company recorded nonrecurring charges of $1,966 and $5,120,
respectively. Excluding these charges, net income and earnings per share
would have been $9,040 and $0.52, respectively, for fiscal year 1994.
(2) Excluding the impact of the discontinuance of the BagEasy product line,
sales growth would have been 20% for fiscal year 1994, 30% for fiscal year
1995 and 29% for the six months ended December 31, 1994.
(3) Product line transfers include sales of certain of the Company's patient
mask products which are accessories for OSA products, non-invasive
ventilatory support products, and resuscitation products.
(4) Including the impact of the nonrecurring charges, net margin was 6% for
fiscal year 1994.
(5) Including the impact of the nonrecurring charges, earnings per share growth
was (37%) for fiscal year 1994, 148% for fiscal year 1995 and 71% for the
six months ended December 31, 1994.
(6) Adjusted to give effect to the sale of 2,000,000 shares of Common Stock by
the Company after deducting underwriting discounts and estimated offering
expenses payable by the Company.
5
<PAGE>
RISK FACTORS
Government Regulation. The development, testing, manufacture and marketing
of the Company's products are subject to extensive regulation and periodic
inspections, principally by the FDA and by corresponding foreign agencies. The
testing for and preparation of required applications can be expensive, and the
subsequent FDA review can be lengthy and uncertain. Moreover, clearance or
approval, if granted, can include significant limitations on the indicated
uses for which a product may be marketed. Failure to comply with applicable
FDA regulations can result in fines, civil penalties, suspensions or
revocation of clearances or approvals, recalls or product seizures, operating
restrictions or criminal penalties. Delays in receipt of, or failure to
receive, clearances or approvals for products for which such clearances or
approvals have not yet been obtained would adversely affect the marketing of
such products and could adversely affect the Company's results of operations
and financial condition. Also, the regulations under the FDA are subject to
change from time to time. For example, a change in the regulations governing
Medical Device Reports ("MDRs") that will impose additional recordkeeping and
reporting requirements on device manufacturers is expected to become effective
in April 1996. This and future changes in FDA regulations could have a
material adverse effect on the Company's operations. See "Business--Regulatory
Matters."
Patent Litigation. In January 1995, ResCare Limited, an Australian
corporation ("ResCare"), instituted litigation alleging that the Company's
basic CPAP product, its nasal mask and an additional feature of the CPAP
product infringe three United States patents owned by or licensed to ResCare.
It is the Company's belief, based upon its investigation, discovery
proceedings conducted in the suit to date and discussions with its counsel,
that the ResCare patents are invalid or unenforceable, and that, even if the
ResCare patents are valid and enforceable, the Company's products do not
infringe the patents. However, there can be no assurance that the ResCare
patents will be declared invalid or unenforceable or that the Company's
products will be found not to infringe the ResCare patents. Because the
products that are the subject of the action represent a significant portion of
the Company's sales, an adverse determination could have a material adverse
effect on the Company's results of operations and financial condition. See
"Business--Legal Proceedings--Patent Litigation."
FDA Warning Letter. Following an inspection of the Company's Murrysville,
Pennsylvania facility completed in August 1994, the FDA issued a "warning
letter" in December 1994 in which it took the position that the Company must
submit additional "510(k) premarket notifications" (under which a product is
cleared for marketing in the U.S. based on the fact that it is substantially
equivalent to another product already being legally marketed) to cover certain
technical features of the Company's BiPAP product and to market its BiPAP
product for ventilatory uses other than the treatment of OSA in adults. The
Company believes that it is in substantial compliance with FDA requirements
relating to its products and that the existing 510(k) clearances for BiPAP
cover the technical features cited in the warning letter and encompass the
marketing of BiPAP products for ventilatory uses in addition to the treatment
of OSA in adults. The Company nevertheless has elected to file 510(k)
submissions for indications in addition to adult OSA and for the technical
features cited in the FDA warning letter. Although there has been no
interruption in the Company's business in the 14 months since receipt of the
warning letter, there can be no assurance that the FDA will not take
enforcement action with respect to the Company's prior or continued marketing
of the BiPAP products or that FDA clearances for the additional 510(k)
premarket notifications that the Company has submitted will be cleared by the
FDA. Sales of BiPAP and related accessories for ventilatory support
applications accounted for approximately 26% of the Company's sales for the
six-month period ended December 31, 1995. See "Business--Regulatory Matters."
Industry Dependence on Third Party Reimbursement. The cost of a significant
portion of medical care in the United States is funded by government and
private insurance programs, such as Medicare, Medicaid and corporate health
insurance programs including health maintenance organizations and managed care
organizations. The Company's future results of operations and financial
condition could be negatively affected by adverse changes made in the
reimbursement policies for medical products under these insurance programs. If
such changes were to occur, the ability of the Company's customers (medical
6
<PAGE>
product distributors and dealers) to obtain adequate reimbursement for the
resale or rental of the Company's products could be affected. In recent years,
limitations imposed on the levels of reimbursement by both government and
private insurance programs have become more prevalent. See "Business--Third
Party Reimbursement."
Industry Consolidation and Customer Concentration. The past several years
have seen a trend toward consolidation in the health care industry generally
and in the Company's customer base in particular. In August 1995, the
Company's two largest customers merged to form a company that in the first six
months of fiscal 1996 accounted for 17% of the Company's revenues, compared
with a combined total of 18% for such two customers in the same period in the
prior fiscal year. Industry consolidation, as well as buying practices by
other large customers, has contributed to a decrease in the average selling
price of certain of the Company's products and correspondingly has placed
pressure on the Company's gross margins. The Company expects this trend to
continue. If the Company is unable to control operating expenses to counteract
the impact of downward pricing, its operating results would be adversely
affected. In addition, a decision by any of the Company's large customers to
significantly reduce its purchases could have a material adverse effect on the
Company's results of operations or financial condition. See "Business--
Customers."
Competition. The Company competes on a product by product basis with various
other companies, some of which may have significantly greater financial and
marketing resources or broader product lines than the Company. Other
manufacturers, including other larger and more experienced manufacturers of
home health care products, have entered the OSA market, and the Company
expects that competition in this market will continue to increase. See
"Business--Competition."
Foreign Operations and Sales. The Company manufactures certain of its
products, principally plastic single-use products, in Hong Kong and in the
Peoples Republic of China. Operations in these locations are subject to the
risks normally associated with foreign operations including, but not limited
to, possible changes in export or import restrictions and the modification or
introduction of other governmental policies with potentially adverse effects.
The Company cannot anticipate the effect on it of the change of sovereignty of
Hong Kong scheduled for 1997. An extended interruption in its foreign
manufacturing operations could have a material adverse effect on the Company's
business. In addition, foreign sales account for approximately 23% of the
Company's revenues. Although substantially all such sales currently are
denominated and collected in U.S. dollars, foreign currency fluctuations could
impact the level of foreign sales. See "Business--Manufacturing."
7
<PAGE>
PRICE RANGE OF COMMON STOCK
The Common Stock is quoted on the Nasdaq National Market. The table below
sets forth, for the quarters indicated, the high and low sales prices per
share of the Common Stock as reported on the Nasdaq National Market.
<TABLE>
<CAPTION>
HIGH LOW
---- ---
<S> <C> <C>
Fiscal Year ended June 30, 1994
First Quarter................................................... $11.63 $ 8.88
Second Quarter.................................................. 10.00 7.88
Third Quarter................................................... 12.00 9.13
Fourth Quarter.................................................. 10.63 8.38
Fiscal Year ended June 30, 1995
First Quarter................................................... $10.63 $ 8.00
Second Quarter.................................................. 12.25 9.75
Third Quarter................................................... 16.88 11.63
Fourth Quarter.................................................. 17.00 10.50
Fiscal Year ended June 30, 1996
First Quarter................................................... $19.75 $13.75
Second Quarter.................................................. 22.25 17.00
Third Quarter (through March 25, 1996).......................... 24.75 17.00
</TABLE>
On March 25, 1996, the last reported sale price of the Common Stock as
reported on the Nasdaq National Market was $21.00 per share. On February 20,
1996, there were approximately 1,400 holders of record of the Common Stock.
USE OF PROCEEDS
The net proceeds to the Company from the sale of the 2,000,000 shares of
Common Stock offered hereby by the Company are estimated to be $39.4 million
($46.8 million if the Underwriters' over-allotment option is exercised in
full), after deducting underwriting discounts and estimated offering expenses
payable by the Company. The Company will not receive any proceeds from the
sale of the 1,030,000 shares of Common Stock offered hereby by the Selling
Stockholders.
The proceeds received by the Company will be added to the Company's working
capital to be used for general corporate purposes, including the acquisition
of similar or related businesses and the acquisition of marketing,
manufacturing or other rights associated with products or technologies which
would complement the Company's products. The proceeds will enable the Company
to take advantage of opportunities which it foresees may develop in these
areas. The Company does not presently have any understandings or agreements
with respect to the acquisition of additional businesses, products or rights.
Pending their use, the proceeds received by the Company will be invested in
short-term, interest bearing money market funds, commercial bank certificates
of deposit or similar investments.
DIVIDEND POLICY
Payment of cash dividends by the Company is subject to the discretion of the
Board of Directors. The current policy of the Board of Directors is to
reinvest all earnings in the development and expansion of the Company's
business. The Company has never paid a cash dividend on its Common Stock, and
its Board of Directors has no present intention of paying cash dividends.
8
<PAGE>
CAPITALIZATION
The following table sets forth the capitalization of the Company at December
31, 1995 and as adjusted to give effect to the sale of 2,000,000 shares of
Common Stock by the Company, after deducting the underwriting discounts and
estimated offering expenses payable by the Company. This table should be read
in conjunction with the Company's Consolidated Financial Statements and the
Notes thereto that appear elsewhere in this Prospectus.
<TABLE>
<CAPTION>
DECEMBER 31, 1995
------------------------
ACTUAL AS ADJUSTED
---------- -------------
(DOLLARS IN THOUSANDS)
<S> <C> <C>
Long-Term Obligations (less current portion)........... $ 5,242 $ 5,242
========== ===========
Shareholders' Equity:
Common Stock, par value $.01 per share, authorized
40,000,000 shares; issued and outstanding 16,851,860
shares at December 31, 1995, and 18,851,860 shares
at December 31, 1995 (as adjusted) (1)............... $ 169 $ 189
Additional Capital.................................... 19,706 59,081
Retained Earnings..................................... 45,675 45,675
---------- -----------
Total Shareholders' Equity............................. 65,550 104,945
---------- -----------
Total Capitalization................................... $ 70,792 $ 110,187
========== ===========
</TABLE>
- --------
(1) Does not include 1,546,626 shares of Common Stock reserved for issuance
under stock options outstanding at December 31, 1995 and 862,688 shares of
Common Stock reserved for future grant under the Company's stock option
plans.
9
<PAGE>
SELECTED FINANCIAL DATA
The selected consolidated financial data presented below for each of the
five years ended June 30, 1995, are derived from the Company's consolidated
financial statements which have been audited by Ernst & Young LLP, independent
auditors. The selected consolidated financial data as of December 31, 1995 and
for the six months ended December 31, 1994 and 1995 have been derived from the
Company's unaudited consolidated financial statements and include all
adjustments, consisting only of normal recurring adjustments, necessary for a
fair presentation of the financial condition and results of operations for
these periods. Operating results for the six months ended December 31, 1995
are not necessarily indicative of the results expected for the entire year.
This data should be read in conjunction with the Consolidated Financial
Statements and Notes thereto and "Management's Discussion and Analysis of
Results of Operations and Financial Condition" appearing elsewhere in this
Prospectus.
<TABLE>
<CAPTION>
(AMOUNTS IN THOUSANDS EXCEPT PER SHARE DATA)
SIX MONTHS ENDED
YEAR ENDED JUNE 30 DECEMBER 31
--------------------------------------------- ------------------
1991 1992 1993 1994 1995 1994 1995
------- ------- ------- ------- ------- -------- --------
INCOME STATEMENT DATA: (UNAUDITED)
<S> <C> <C> <C> <C> <C> <C> <C>
Net sales............... $36,031 $48,976 $69,286 $78,171 $99,450 $ 45,538 $ 56,916
Cost of goods sold...... 17,554 23,360 32,114 34,830 43,077 19,660 24,896
------- ------- ------- ------- ------- -------- --------
18,477 25,616 37,172 43,341 56,373 25,878 32,020
General & administrative
expenses............... 5,295 6,538 10,581 10,028 14,050 6,812 7,848
Sales, marketing &
commission expenses.... 6,045 9,211 12,313 15,069 17,696 8,299 9,513
Research & development
expenses............... 1,646 2,311 3,556 4,794 7,077 3,060 4,061
Nonrecurring charges.... -0- -0- -0- 7,086(1) -0- -0- -0-
Interest expense........ 300 201 176 171 194 96 101
Other income............ (362) (704) (550) (623) (1,179) (510) (533)
------- ------- ------- ------- ------- -------- --------
12,924 17,557 26,076 36,525 37,838 17,757 20,990
------- ------- ------- ------- ------- -------- --------
Income before income
taxes............... 5,553 8,059 11,096 6,816 18,535 8,121 11,030
Income taxes............ 1,782 2,696 3,717 2,075 6,858 3,005 4,302
------- ------- ------- ------- ------- -------- --------
Net income............ $ 3,771 $ 5,363 $ 7,379 $ 4,741(1) $11,677 $ 5,116 $ 6,728
======= ======= ======= ======= ======= ======== ========
Earnings per share...... $ 0.26 $ 0.31 $ 0.43 $ 0.27(1) $ 0.67 $ 0.29 $ 0.38
======= ======= ======= ======= ======= ======== ========
Weighted average shares
of Common Stock
outstanding and
equivalents............ 14,631 17,057 17,319 17,281 17,532 17,346 17,730
</TABLE>
<TABLE>
<CAPTION>
JUNE 30
--------------------------------------- DECEMBER 31
1991 1992 1993 1994 1995 1995
------- ------- ------- ------- ------- -----------
BALANCE SHEET DATA: (UNAUDITED)
<S> <C> <C> <C> <C> <C> <C>
Working capital......... $16,086 $19,979 $25,172 $31,032 $39,413 $44,146
Total assets............ 36,140 43,462 54,331 58,917 78,039 83,952
Total long-term
obligations............ 4,535 4,291 4,288 4,854 5,538 5,242
Total shareholders'
equity................. 25,799 31,391 39,148 44,224 58,369 65,550
</TABLE>
- --------
(1) In the first quarter of fiscal year 1994, the Company recorded
nonrecurring charges related to the discontinuance of its BagEasy product
line. In the fourth quarter of fiscal year 1994, the Company recorded
nonrecurring charges for the write-off of a prepayment for inventory under
the terms of a distribution agreement. See Note I and Note J to the
Consolidated Financial Statements for additional information regarding
these nonrecurring charges. Excluding these charges, net income and
earnings per share would have been $9,040 and $0.52, respectively, for
fiscal year 1994.
10
<PAGE>
MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL
CONDITION
GENERAL
Statements in this section and elsewhere in this Prospectus about the
Company's belief or expectations or about whether any particular event or
circumstance is likely to occur or continue are forward-looking statements
that are subject to risks and uncertainties. For a discussion of factors that
could cause actual results to vary materially, see "Risk Factors" above.
The Company's revenues are derived from the sale of medical devices used for
the treatment of patients suffering from respiratory disorders. The Company's
primary product lines are devices for the treatment of OSA, non-invasive
ventilatory support devices, patient mask products for OSA and non-invasive
ventilatory support therapy and single-use resuscitation products.
The OSA product line and related accessories comprise the largest portion of
the Company's sales and are growing rapidly, accounting for 68% of total sales
for the six months ended December 31, 1995 versus 57% of sales for fiscal year
1993. Non-invasive ventilatory support products and related accessories are
the next largest product line and are growing rapidly as well, accounting for
26% of sales for the six months ended December 31, 1995 versus 23% of sales
for fiscal year 1993.
The Company's sales currently are comprised of 68% equipment and 32%
consumable and single-use products. Consumable and single-use products consist
primarily of patient masks and related accessories used with the Company's OSA
and non-invasive ventilatory support devices, disposable anesthesia masks and
the BagEasy manual resuscitator and are an important component of the
Company's business. The Company expects to continue to derive significant
sales revenue from consumable and single-use products.
The Company exports its products to foreign markets, primarily Europe,
Canada and the Far East. International sales have increased from 18% of net
sales in fiscal year 1993 to 20% of net sales in fiscal year 1995 and 23% of
net sales for the six months ended December 31, 1995. The Company expects its
international sales to grow at least as fast as overall sales, consistent with
its strategy of expanding its international distribution and manufacturing
organization.
The Company's gross margin percentage has increased from 54% of sales for
fiscal year 1993 to 57% of sales for fiscal year 1995, principally due to a
shift in sales mix over the period to the Company's higher margin products and
to increased operating leverage. For the six months ended December 31, 1995,
the gross margin percentage declined to 56% of sales, principally due to
decreasing average selling prices for certain of the Company's major products.
The Company believes that downward pressure on gross margins is likely to
continue, primarily due to decreases in selling prices resulting from
increased purchasing influence of major customers, competition in the
Company's major product lines and continuing efforts by third party and
government payors to control reimbursement for medical products and services,
including products sold by the Company. Despite this downward pressure on
gross margins, operating income increased from 17% of sales for the six months
ended December 31, 1994 to 19% for the period ended December 31, 1995. This
increase in operating income as a percent of sales is due to operating
expenses increasing at rates less than the rate of growth in sales. In future
periods, it is the Company's intent to focus on continuing to control
operating expenses to counteract the downward pressure on gross margins.
11
<PAGE>
RESULTS OF OPERATIONS
The following table sets forth, for the periods indicated, the percentage of
net sales represented by items in the Consolidated Statements of Operations.
<TABLE>
<CAPTION>
SIX MONTHS
YEAR ENDED ENDED
JUNE 30 DECEMBER 31
---------------- -------------
1993 1994 1995 1994 1995
---- ---- ---- ----- -----
<S> <C> <C> <C> <C> <C>
Net sales..................................... 100% 100% 100% 100% 100%
Cost of goods sold............................ 46 45 43 43 44
--- --- --- ----- -----
Gross profit.................................. 54 55 57 57 56
General and administrative expenses........... 15 13 14 15 14
Sales, marketing and commission expenses...... 18 19 18 18 17
Research and development expenses............. 5 6 7 7 7
Nonrecurring charges.......................... 0 9 0 0 0
Interest expense.............................. 0 0 0 0 0
Other income.................................. 0 (1) (1) (1) (1)
--- --- --- ----- -----
INCOME BEFORE INCOME TAXES.................. 16 9 19 18 19
Income taxes.................................. 5 3 7 7 7
--- --- --- ----- -----
NET INCOME................................ 11% 6% 12% 11% 12%
=== === === ===== =====
</TABLE>
Six Months Ended December 31, 1995 vs. Six Months Ended December 31, 1994
Net sales for the six months ended December 31, 1995 were $56,916,000, an
increase of 25% over the $45,538,000 recorded in the year earlier period. The
increase in net sales was primarily attributable to increases in total unit
and dollar sales for the Company's OSA and non-invasive ventilatory support
products. Sales of the Company's face masks and other patient interface
devices used as accessories for its OSA and non-invasive ventilatory support
units increased significantly during this period in both unit and dollar
terms.
The Company's gross profit for the six months ended December 31, 1995 was
56% of net sales as compared to 57% of net sales for the year earlier period.
The decrease in the gross profit percentage was caused by reduced average
selling prices, primarily for the Company's REMstar Nasal CPAP systems, during
the current quarter and six-month period. These reductions in average selling
prices resulted from increasing competition in the OSA market, particularly
relative to the Company's large, national customers who receive lower prices
in exchange for volume purchase commitments.
General and administrative expenses were $7,848,000 (14% of net sales) for
the six months ended December 31, 1995 as compared to $6,812,000 (15% of net
sales) for the year earlier period. The decrease in these expenses as a
percentage of net sales reflects the Company's ability, during the current
six-month period, to limit spending increases in these areas to rates less
than the rate of sales increase. The increase in absolute dollars was due
primarily to increased legal fees incurred relating to the previously
disclosed patent litigation.
Sales, marketing and commission expenses were $9,513,000 (17% of net sales)
for the six months ended December 31, 1995 as compared to $8,299,000 (18% of
net sales) for the year earlier period. The decrease in these expenses as a
percentage of net sales reflects the Company's ability, during the current
six-month period, to limit spending increases in these areas to rates less
than the rate of sales increase. The increase in absolute dollars was due
primarily to costs associated with trade shows and related travel expenses,
salary expenses for new employees and commission expenses based on higher
sales levels achieved.
12
<PAGE>
Research and development expenses were $4,061,000 (7% of net sales) for the
six months ended December 31, 1995 as compared to $3,060,000 (7% of net sales)
for the year earlier period. The increase in absolute dollars reflects the
extensive new product development efforts during the period and currently
underway to support new product introductions in the Company's major product
groups and also to explore opportunities in other respiratory product areas.
Several new products have been introduced during the current fiscal year, and
other new product introductions are scheduled for the remainder of the fiscal
year, in some cases with initial distribution limited to international markets
until regulatory clearance to market in the United States is obtained.
Subsequent to the end of the six-month period ended December 31, 1995, the
Company received clearance from the FDA to market its new Aria CPAP System and
two new face mask products in the United States.
The Company's effective income tax rate was 39% for the six months ended
December 31, 1995 as compared to 37% for the year earlier period. Changes in
the Company's effective income tax rate are due primarily to changes in the
relative proportion of the Company's taxable income attributable to its United
States operation versus taxable income attributable to its Hong Kong and
Peoples Republic of China operations. The United States operation pays income
taxes at a higher rate (approximately 41% before available income tax credits)
than do the Hong Kong and Peoples Republic of China operations. During the six
months ended December 31, 1995, the proportion of taxable income attributable
to the United States operation increased. In addition, the research and
development tax credit expired effective July 1, 1995. This income tax credit
had been available during prior fiscal years to reduce income taxes paid by
the United States operation and therefore reduced the effective income tax
rate.
As a result of the factors described above, the Company's net income was
$6,728,000 (12% of net sales) for the six months ended December 31, 1995 as
compared to $5,116,000 (11% of net sales) for the six months ended December
31, 1994.
Fiscal 1995 vs. Fiscal 1994 and Fiscal 1993
Net sales for fiscal year 1995 were $99,450,000, representing a 27% increase
in net sales over the $78,171,000 recorded in fiscal year 1994. Fiscal year
1994 net sales represented a 13% increase over the $69,286,000 recorded in
fiscal year 1993.
The increase in net sales from fiscal year 1994 to fiscal year 1995 was
primarily attributable to increases in total unit sales of the Company's OSA
and non-invasive ventilatory support products and reflects sales growth across
all of the Company's market bases for these product groups. In addition, sales
of the Company's face mask products, including those used as accessories for
its OSA and non-invasive ventilatory support products and those manufactured
and sold on an OEM basis (disposable anesthesia masks), increased in both unit
and dollar terms. Finally, the overall increase in net sales was accomplished
in spite of a decrease in sales of the Company's resuscitation products
resulting from the Company's November 1993 decision to discontinue production
and shipment of its BagEasy line of disposable manual resuscitators, which
accounted for 2% of net sales for fiscal year 1994. Excluding the impact of
the discontinuance of the BagEasy product line, sales growth would have been
30% and 20% for fiscal years 1995 and 1994, respectively. In March 1995, the
Company introduced a redesigned version of the BagEasy product, and sales for
this redesigned version accounted for less than one-half of one percent of
fiscal year 1995 sales.
The increase in net sales from fiscal year 1993 to fiscal year 1994 was also
primarily attributable to increases in total unit sales for the Company's OSA
and non-invasive ventilatory support products. Sales of resuscitation products
decreased from fiscal year 1993 to fiscal year 1994 as a result of the
discontinuance of the BagEasy manual resuscitator product discussed above
(BagEasy accounted for 8% of net sales for fiscal year 1993). Finally, sales
of the Company's disposable anesthesia masks decreased in both unit and dollar
terms from fiscal year 1993 to fiscal year 1994 due primarily to reduced
orders from the Company's customer for disposable anesthesia masks. The
reduction in disposable anesthesia mask sales was also due
13
<PAGE>
to a reduction in the unit selling price of the masks under the terms of the
June 1993 supply agreement with the Company's sole customer for these masks.
Under the 1993 agreement, the customer may choose to pay a lower unit price
for the masks in exchange for assuming responsibility for freight and duty
costs related to mask shipments.
The Company's gross profit was 57% of net sales for fiscal year 1995 as
compared to 55% of net sales for fiscal year 1994 and 54% of net sales for
fiscal year 1993. The increases in gross profit percentage were due primarily
to the Company's ability to limit the growth of its manufacturing support
costs to rates less than the rate of sales increases achieved and a shift in
sales mix toward the Company's higher margin products. In addition, the
increase in fiscal year 1994 gross profit was partially offset by a temporary
diversion of engineering resources away from research and development
activities and to manufacturing support activities in response to
recommendations resulting from an FDA inspection.
General and administrative expenses were $14,050,000 (14% of net sales) for
fiscal year 1995 as compared to $10,028,000 (13% of net sales) for fiscal year
1994 and $10,581,000 (15% of net sales) for fiscal year 1993. The increase in
these costs from fiscal year 1994 to fiscal year 1995 was due to a provision
for year-end profit sharing bonuses and to higher administrative costs related
to the growth of the Company, including staffing increases, increased legal
fees, and increased provisions for uncollectible accounts receivable. The
decrease in these costs, both in absolute dollars and as a percentage of net
sales, from fiscal year 1993 to fiscal year 1994 was due primarily to the
absence of profit sharing bonuses in fiscal year 1994 based on financial
results achieved in that year.
Sales, marketing and commission expenses were $17,696,000 (18% of net sales)
for fiscal year 1995 as compared to $15,069,000 (19% of net sales) for fiscal
year 1994 and $12,313,000 (18% of net sales) for fiscal year 1993. These
increases in absolute dollars were due to increased commission expenses paid
to independent sales representatives resulting from a shift in sales mix
towards products handled by these representatives, increased trade show and
training expenses, increased salary expenses for new employees in sales and
marketing management, and, for the fiscal year 1994 to fiscal year 1995
comparison, product literature and advertising expenses incurred in
anticipation of new product launches.
Research and development expenses were $7,077,000 (7% of net sales) for
fiscal year 1995 as compared to $4,794,000 (6% of net sales) for fiscal year
1994 and $3,556,000 (5% of net sales) for fiscal year 1993. The continuing
increases in research and development spending reflect the Company's
commitment to investment in future product development and product
enhancements in all of the Company's major product groups. Extensive new
product development efforts were conducted during fiscal years 1994 and 1995
in anticipation of new product introductions in each major product group
during calendar year 1995. Development work was conducted on new families of
OSA and non-invasive ventilatory support devices and the redesigned BagEasy
manual resuscitator. Certain new models of the OSA devices were introduced in
the first quarter of fiscal year 1996, the redesigned BagEasy manual
resuscitator was introduced in March 1995, and a variety of patient interface
devices were introduced at various times during the three-year period.
Additional costs were also incurred throughout the three-year period to fund
clinical studies. Finally, the increase from 1994 to 1995 resulted, to a
lesser extent, from the temporary diversion during fiscal year 1994 of
engineering resources away from research and development activities and to
manufacturing support activities in response to recommendations resulting from
an FDA inspection.
Nonrecurring charges totaled $7,086,000 (9% of net sales) for fiscal year
1994. The first component of these charges, recorded in the first quarter,
totaled $1,966,000 and represented costs incurred by the Company in connection
with its November 1993 decision, discussed above, to discontinue the
production and sale of its BagEasy line of manual resuscitators and recall all
remaining BagEasy products in distribution channels and customer inventories
and included provisions for write-offs of inventories and fixed assets, the
satisfaction of purchase order and compensation commitments, and costs
associated with the recall. The second component of these nonrecurring
charges, recorded in the fourth quarter of fiscal year 1994,
14
<PAGE>
totaled $5,120,000 and represented the write-off of the remaining balance on
the prepayment for inventory and the net book value of units that had been
purchased under the terms of a distribution agreement. See Notes I and J to
the Consolidated Financial Statements for additional information regarding
these charges. The Company did not incur any nonrecurring charges in fiscal
years 1995 or 1993.
The Company's effective income tax rate was 37% for fiscal year 1995 as
compared to 30% for fiscal year 1994 and 33% for fiscal year 1993. Changes in
the Company's effective income tax rate were due primarily to changes in the
relative proportions of taxable income attributable to its United States
operation versus taxable income attributable to its Hong Kong and Peoples
Republic of China operations because the United States operation pays income
taxes at a higher rate (approximately 41% before available income tax credits)
than do the Hong Kong and Peoples Republic of China operations. The proportion
of taxable income attributable to the United States operation has increased,
with the exception of fiscal year 1994. During that year, the nonrecurring
charges described above were incurred almost exclusively by the United States
operation, reducing taxable income attributable to the U.S. operation and
correspondingly reducing the Company's overall effective income tax rate.
As a result of the factors described above, the Company's net income was
$11,677,000 (12% of net sales) for fiscal year 1995 as compared to $4,741,000
(6% of net sales) for fiscal year 1994 and $7,379,000 (11% of net sales) for
fiscal year 1993.
FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES
The Company had working capital of $44,146,000 at December 31, 1995 and
$39,413,000 at June 30, 1995. Net cash used by operating activities was
$2,846,000 for the six months ended December 31, 1995 as compared to net cash
provided by operating activities of $3,295,000 for the six months ended
December 31, 1994. The net use of cash for the six-month period ended December
31, 1995 was due primarily to increases in inventories and accounts receivable
in amounts greater than the changes in those accounts during the first six
months of last fiscal year.
The increase in trade accounts receivable in the six-month period comparison
was due to growth in international sales at a rate greater than total sales
(all international sales are made on extended payment terms) and to a
continued increase in the portion of the Company's domestic sales that are
being made on extended payment terms. The increase in inventories was due to
the Company's purchase of raw materials for, and the initial production of,
many of its new products, including those introduced during the current six-
month period and those scheduled for introduction during the remainder of the
fiscal year.
The Company had working capital of $39,413,000 and $31,032,000 at June 30,
1995 and 1994, respectively. Net cash provided by operating activities was
$9,469,000, $4,568,000 and $10,669,000 for fiscal years 1995, 1994 and 1993,
respectively. The increase in cash provided by operating activities from
fiscal year 1994 to fiscal year 1995 was due to an increase in net income, a
decrease in refundable income taxes, and increases in accounts payable and
accrued expenses during fiscal year 1995 as compared to decreases or smaller
increases in those liability accounts during fiscal year 1994. The reduction
in cash provided by operating activities from fiscal year 1993 to fiscal year
1994 was due primarily to increases in accounts receivable and refundable
income taxes as well as decreases in accounts payable and accrued expenses.
Trade accounts receivable increased from June 30, 1994 to June 30, 1995 at a
rate greater than the percentage change in sales for the fiscal years ending
on those dates primarily because the Company's quarterly sales were at their
highest level for those two fiscal years during the last quarter of fiscal
year 1995. In addition, the aging of the Company's receivables increased as a
result of extended payment terms offered by the Company under several flexible
financing programs.
15
<PAGE>
Net cash used by investing activities was $3,604,000 for the six months
ended December 31, 1995 as compared to $2,974,000 for the six months ended
December 31, 1994. Essentially all of the cash used by investing activities
for both periods represented capital expenditures, including the purchase of
production equipment, computer and telecommunications equipment and office
equipment. The funding for capital expenditures in the current six-month
period was provided by accumulated cash and short-term investment balances,
and in the first six months of last fiscal year was provided by positive cash
flows from operating activities and by accumulated cash and short-term
investment balances.
Net cash used by investing activities was $7,711,000, $8,415,000, and
$6,363,000 for fiscal years 1995, 1994 and 1993, respectively. Net cash used
for capital expenditures was $6,941,000, $7,735,000 and $6,363,000 for the
respective years. Approximately $2,643,000 of the capital expenditures for
fiscal year 1995 and $1,203,000 of the capital expenditures for fiscal year
1993 were for the purchase and development of additional land and expansion
costs related to the Company's headquarters and manufacturing facility in
Murrysville, Pennsylvania. The remainder of the significant capital
expenditures for fiscal years 1995, 1994 and 1993 were for the purchase of
production equipment, office equipment and computers. In addition, fiscal year
1995 investing activities included an expenditure of $745,000 representing a
portion of the purchase price of an acquired business plus related acquisition
expenses. The remainder of the purchase price was paid with shares of the
Company's Common Stock. See Note L to the Consolidated Financial Statements
for additional information about this acquisition.
In November 1993, the Company completed a 46,000 square foot addition to its
headquarters and manufacturing facility in Murrysville, Pennsylvania.
Financing for the addition includes a $978,000 Redevelopment Authority loan
that was received in June 1994 and a $1,100,000 loan that was received from
the Pennsylvania Industrial Development Authority in February 1995. Both loans
have a 2% fixed interest rate and a 15-year repayment term. See Note D to the
Consolidated Financial Statements for additional information about the
Company's long-term obligations. Funding for the remainder of the facility
addition and the other capital expenditures was provided by positive cash
flows from operating activities and from cash and short-term investment
balances.
Net cash provided by financing activities also includes proceeds from the
issuance of Common Stock under the Company's stock option plans and the
receipt of a minority interest investment in a joint venture and is reduced by
payments made on long-term obligations. In October 1995, the Company entered
into a new line of credit facility with a commercial bank that provides for
the availability of $1,250,000 at the bank's prime interest rate until the
expiration date of the agreement on October 31, 1996. The Company expects that
this line of credit facility will be renewed upon its expiration. See Note D
to the Consolidated Financial Statements for a discussion of the line of
credit.
As discussed above, in November 1993 the Company discontinued the production
and sale of its BagEasy line of manual resuscitators and recalled all
remaining BagEasy products in distribution channels and customer inventories.
The BagEasy product represented approximately 8% of the Company's total sales
for the year ended June 30, 1993 (the last full fiscal year it was sold) and
did not make significant contributions to profitability. In March 1995, the
Company began shipping a redesigned version of the BagEasy manual
resuscitator.
The Company has not provided a valuation allowance for deferred income tax
assets because it has determined that it is more likely than not that such
assets can be realized, at a minimum, through carrybacks to prior years in
which taxable income was generated.
The Company believes that positive cash flow from operating and financing
activities, its $1,250,000 line of credit facility, and its accumulated cash
and short-term investments will be sufficient to meet its current and
presently anticipated needs for the next 12 months for operating activities,
investing activities and financial activities (primarily consisting of
payments on long-term debt).
16
<PAGE>
INFLATION
Inflation has not had a significant effect on the Company's business during
the periods discussed.
QUARTERLY RESULTS OF OPERATIONS
The following table sets forth selected operating results for the ten
quarters ending December 31, 1995. In the opinion of the Company's management,
this unaudited information has been prepared on the same basis as the audited
financial information, and includes all adjustments (consisting only of
normal, recurring adjustments) necessary to present this information fairly.
This financial information should be read in conjunction with the Company's
Consolidated Financial Statements and Notes thereto appearing elsewhere in
this Prospectus. These operating results are not necessarily indicative of
results for any future period.
(IN THOUSANDS EXCEPT PER SHARE DATA)
<TABLE>
<CAPTION>
THREE MONTHS ENDED
------------------------------------------
SEPTEMBER 30 DECEMBER 31 MARCH 31 JUNE 30
1993 1993 1994 1994
------------ ----------- -------- -------
<S> <C> <C> <C> <C>
Net sales......................... $18,224 $18,600 $19,308 $22,039
Gross profit...................... 9,989 10,100 10,704 12,547
Nonrecurring charges.............. 1,966(1) -0- -0- 5,120(2)
Net income (loss)................. 873 2,064 2,244 (440)
Earnings (loss) per share......... $ 0.05 $ 0.12 $ 0.13 $ (0.03)
<CAPTION>
THREE MONTHS ENDED
------------------------------------------
SEPTEMBER 30 DECEMBER 31 MARCH 31 JUNE 30
1994 1994 1995 1995
------------ ----------- -------- -------
<S> <C> <C> <C> <C>
Net sales......................... $21,670 $23,868 $25,599 $28,313
Gross profit...................... 12,199 13,679 14,486 16,009
Net income........................ 2,420 2,696 3,072 3,489
Earnings per share................ $ 0.14 $ 0.15 $ 0.17 $ 0.20
<CAPTION>
THREE MONTHS ENDED
-------------------------
SEPTEMBER 30 DECEMBER 31
1995 1995
------------ -----------
<S> <C> <C>
Net sales......................... $26,675 $30,241
Gross profit...................... 15,160 16,860
Net income........................ 3,219 3,509
Earnings per share................ $ 0.18 $ 0.20
</TABLE>
(1) In the three months ended September 30, 1993, the Company recorded
nonrecurring charges related to the discontinuance of its BagEasy product
line. See Note J to the Consolidated Financial Statements for additional
information regarding these nonrecurring charges.
(2) In the three months ended June 30, 1994, the Company recorded nonrecurring
charges for the write-off of a prepayment for inventory under the terms of
a distribution agreement. See Note I to the Consolidated Financial
Statements for additional information regarding these nonrecurring
charges.
17
<PAGE>
BUSINESS
Respironics is a leading developer, manufacturer and marketer of medical
devices used for the treatment of patients suffering from certain respiratory
disorders. The Company's products are designed to reduce costs while improving
the effectiveness of patient care and are used primarily in the home and
hospitals, as well as emergency medical settings and alternative care
facilities. The Company's primary product lines are: (i) continuous positive
airway pressure ("CPAP") devices and bi-level positive airway pressure
("BiPAP") devices for the treatment of obstructive sleep apnea ("OSA"), a
serious disorder characterized by the repeated cessation of breathing during
sleep; (ii) bi-level non-invasive ventilatory support devices; (iii) patient
mask products; and (iv) single-use resuscitation products. Respironics markets
its products through a sales organization consisting of approximately 90
direct and independent sales representatives, who sell to a network of over
2,500 medical product dealers. The Company's sales have grown from $36.0
million in fiscal year 1991 to $99.5 million in fiscal year 1995 and are
currently comprised of 68% equipment and 32% consumable and single-use
products. With approximately 85% of its sales currently reaching the home care
market, Respironics believes that it is well-positioned to take advantage of
the growing preference for in-home treatment of patients suffering from
respiratory disorders.
COMPANY'S MARKET
The Company competes in the respiratory products market, which was estimated
in 1995 to be approximately $2 billion annually in the U.S. Growth in this
market has been driven by the aging U.S. population and the shift in treatment
to lower cost delivery sites such as post-acute facilities and the home. This
shift has resulted from increasing pressure to reduce escalating health care
costs and has been enabled by improvements in technology which permit the
delivery of high quality care in non-hospital environments. Within the overall
respiratory products market, the Company's products compete in the OSA, non-
invasive ventilatory support, patient mask and resuscitation segments.
Obstructive Sleep Apnea
It is estimated that devices for the treatment of OSA constitute a $100
million annual U.S. market that is growing at 20 to 25% per year. This growth
is driven primarily by the increasing recognition by the medical community and
the general public of the prevalence of, and the serious medical complications
resulting from, OSA. Although an increasing number of OSA cases are being
diagnosed and treated, the National Commission on Sleep Disorders Research has
indicated that the vast majority of patients with sleep disorders currently
remain undiagnosed. OSA is a serious disorder caused by obstruction of the
upper airway during sleep. The condition is characterized by cycles of heavy
snoring, obstructive choking (apnea) and partial awakening. OSA sufferers can
experience hundreds of these cycles every night, resulting in repeated
arousals from sleep that lead to debilitating daytime sleepiness, which in
turn impairs functioning and has been linked to increased industrial and
automobile accidents. The National Commission has also indicated that OSA may
lead to higher incidence of strokes, heart disease and other serious medical
conditions.
According to a January 1993 report by the National Commission, more than 18
million people in the U.S. have symptoms which are consistent with a diagnosis
of some degree of OSA. An April 1993 study published in the New England
Journal of Medicine concluded that 4% of men and 2% of women in the middle-
aged work force suffer from a clinically important degree of sleep apnea.
Other studies have shown that OSA also occurs in infants, children and the
elderly.
In 1985, Respironics introduced the first commercially available CPAP
product designed for the treatment of OSA as an alternative to a surgical
technique referred to as uvulopalatopharyngoplasty ("UP3"), the standard
surgical method of treatment available at that time. UP3 involves a procedure
18
<PAGE>
performed on the upper airway of a patient to remove excess tissue and to
streamline the shape of the airway. The treatment of OSA with CPAP involves
the use of a small portable air compressor to supply room air at a
predetermined positive pressure to a sleeping patient through flexible tubing
and a comfortably fitting mask. The continuous positive airway pressure
applied in this manner acts as a pneumatic splint, keeping the nasopharyngeal
airway open and unobstructed throughout the breathing cycle.
Diagnosis of OSA and other forms of sleep disorders is usually made by
overnight testing with a multichannel recorder in a sleep disorders
laboratory. Patients are referred to a sleep laboratory by their family
physician or by a pulmonologist, neurologist or psychiatrist. The number of
sleep labs in the U.S. has grown dramatically during the past decade. The
Company estimates that there are currently approximately 1,300 sleep labs in
the U.S., up from 450 in 1988. Patients diagnosed with OSA for whom nasal CPAP
treatment is prescribed usually undergo a second night's testing in the sleep
laboratory to confirm that the treatment is effective and to determine the
level of CPAP that they require. Currently, there is a trend for more testing
to be performed in the home with portable monitoring units. These home studies
may either be attended by a sleep technician or unattended with the recorded
patient data ultimately transferred to a diagnostic unit for analysis by a
sleep professional. The U.S. market for sleep disorder related diagnostic and
monitoring devices is estimated to be $30 to $40 million annually.
Non-Invasive Ventilatory Support
The overall U.S. ventilation market is estimated to be $250 million
annually. Ventilators are used to augment or maintain patient breathing. Non-
invasive ventilatory support is an emerging sector of the overall ventilation
market, and is currently estimated to be approximately 10% of that market. In
1989, Respironics introduced the first non-invasive bi-level ventilatory
support device specifically designed to compensate for mask leaks. Growth
factors in the non-invasive ventilatory support market consist primarily of
the growing awareness in the medical community of the benefits of non-invasive
ventilatory support over traditional invasive ventilation and the aging of the
U.S. population with the resultant need for ventilatory assistance. While
certain critically ill patients require invasive ventilation, non-invasive
devices may be able to provide ventilatory assistance to certain patients who
are not dependent on a ventilator for continuous life support. Non-invasive
ventilatory support is provided through an external nasal mask and therefore
does not involve intubation.
Patient Masks
The markets served by the Company's patient mask products include the
delivery of CPAP and non-invasive ventilatory support therapy using the BiPAP
Ventilatory Support System, the delivery of emergency resuscitation to
patients who have stopped breathing and the delivery of anesthesia gases to
patients before, during and after surgical procedures. The use of patient
masks in the delivery of CPAP and BiPAP therapy has increased, and the Company
expects that this usage will continue to increase as new applications for such
therapy are identified and cleared for marketing by the FDA and also as the
installed base of the Company's CPAP products and BiPAP Ventilatory Support
Systems in the field grows.
Resuscitation
The market for manual resuscitators is estimated to be $50 million annually
and growing at 8 to 10% per year. Growth in this market is driven primarily by
concerns in the medical community about cross-contamination and the resulting
preference for products that are used by only one patient, including those
used once and then disposed of and those used several times by one patient and
then disposed of. The market served by the Company's resuscitation products
consists primarily of the market for disposable manual resuscitators,
including the Company's BagEasy product. Manual resuscitators are used to
ventilate the lungs of a patient by squeezing a self-inflating bag connected
to a patient mask or endotracheal tube. These devices can be used to
resuscitate patients who have stopped breathing and to sustain proper
breathing function for a short period of time, typically during transport, in
critically ill patients.
19
<PAGE>
STRATEGY
Respironics' objective is to be the market leader in innovative devices for
the treatment of respiratory disorders. The Company's strategy is to: (i)
continue to commit significant resources to the development of innovative
products; (ii) expand the breadth of its product lines to address the full
range of respiratory disorders; (iii) expand its international distribution
and manufacturing capabilities; (iv) pursue acquisitions of complementary
technologies, products and businesses; (v) enhance operational quality and
efficiency through process excellence; and (vi) develop partnering
relationships with customers.
Develop Innovative Products. Respironics has established a record of
innovation in respiratory care and is committed to developing next-generation
respiratory devices that offer significant competitive advantages over
currently available products. The Company has consistently increased research
and development expenditures and expects to maintain research and development
spending at significant levels. The Company recently began introducing its new
generation of OSA products, the Great Performers line, and is currently
developing its next-generation family of non-invasive ventilatory support
devices which it expects to introduce in international markets in summer 1996.
The new OSA products include a CPAP device, Virtuoso, that will incorporate
automatic feedback technology, an important technological advance in OSA
therapy. The Company believes that innovation will allow it to maintain its
leading market position.
Expand the Breadth of Its Product Lines. The Company plans to broaden its
current product lines and to add new product lines to address an increasing
range of respiratory disorders through new product development or acquisition
of technologies and products. These products will be offered at multiple price
points throughout the entire spectrum of health care delivery locations, from
hospitals and post-acute facilities to sleep labs to the home. The Company's
goal is to have the best products available for treating patients at each
health care delivery site. The Company believes that expanding the breadth of
its product lines will enable it to better meet the needs of the marketplace
and leverage its existing distribution network.
Expand International Distribution and Manufacturing
Capabilities. Respironics intends to expand its position in international
markets by capitalizing on its established distribution and manufacturing
infrastructure. The Company's international distribution organization consists
of over 100 distributors in 58 countries worldwide. Over the past 24 months,
the Company has significantly expanded its international staff and established
new distribution relationships. International sales represented 23% of revenue
for the six-month period ended December 31, 1995, up from 20% in the prior
year's comparable period. In January 1996, the Company received ISO 9001
certification from the International Organization of Standards and, at the
same time, received authorization under the European Union's Medical Device
Directives to affix the "CE Mark" to the Company's products marketed
throughout the world. The Company believes that expansion of its international
capabilities will enable it to capitalize on growth opportunities in both
existing and developing foreign markets.
Acquire Complementary Technologies, Products and Businesses. Respironics
intends to pursue the acquisition of technologies, products and entire
businesses. The Company believes that, as consolidation within the medical
technology industry continues, there will be attractive acquisitions available
to complement the Company's current product offerings. Consistent with this
strategy, in 1995 the Company completed the acquisition of Vitalog, a
developer, manufacturer and marketer of monitoring and diagnostic devices for
sleep and other respiratory disorders. The Company believes acquisitions will
allow it to quickly broaden its product lines and leverage its existing
distribution network.
Enhance Operational Quality and Efficiency Through Process
Excellence. Respironics' management continuously reviews key aspects of the
Company's operations, such as manufacturing, marketing and research and
development, to determine whether certain processes can be performed more
efficiently. The Company has implemented a series of process improvements in
several operational areas that have resulted in cost efficiencies. The Company
believes these continuous process improvements will
20
<PAGE>
enhance its reputation as a high-quality supplier while contributing to its
ability to maintain its operating margins.
Develop Partnering Relationships with Customers. The Company intends to
continue to expand the scope of its relationships with its customers by
becoming an active partner with these customers as they distribute, service
and support the Company's products. These partnering activities have taken a
variety of forms to date, including providing training and medical education
programs for the customers' staffs and sales forces and maintaining a
consistent record of shipping over 90% of customer orders within 24 hours of
receipt. The Company believes these partnering relationships and programs help
to positively differentiate it from the other participants in the marketplace
and allow the Company to maintain and improve its competitive position. The
Company plans to expand the scope of these activities, particularly as the
Company's customer base consolidates.
PRODUCTS
The Company's principal products are described in the following table:
<TABLE>
<CAPTION>
PRODUCT DESCRIPTION DELIVERY SITES
------- ----------- --------------
<C> <S> <C>
OBSTRUCTIVE
SLEEP APNEA
REMstar Choice Small portable air pressurization CPAP Home
CPAP System therapy unit. Features a cordless remote
controller, air pressure stability, minimal
operating noise and consumer-oriented
design. Six models, retailing for $700 to
$1,300.
Aria CPAP System Lightweight, compact and quiet Home
microprocessor-driven CPAP system. Features
easy set up, built-in memory to record
patient usage data, dual time meters and
LCD display. First product introduction in
the Great Performers series. Currently
being distributed in international markets.
Recently received 510(k) clearance and
expected to begin selling into the U.S.
market in spring 1996.
Virtuoso Smart Self-adjusting CPAP system providing three Home and sleep labs
CPAP System different therapy modes. Tracks patients'
changing needs and automatically adjusts
the pressure level, providing appropriate
therapy over time. Includes built-in memory
to record patient usage/therapy data.
Currently sold internationally and is
pending 510(k) clearance.
BiPAP S Airway BiPAP unit with automatic compensation for Home and sleep labs
Management System mask leaks. Used to treat severe cases of
OSA with bi-level pressure, which is more
comfortable to the patient than higher
pressures of CPAP therapy. Two models,
retailing for $2,800 to $3,000.
</TABLE>
21
<PAGE>
<TABLE>
<CAPTION>
PRODUCT DESCRIPTION DELIVERY SITES
------- ----------- --------------
<C> <S> <C>
Cricket Oximeter and Lightweight, portable and battery powered Home, hospitals and
HMS 5000 Monitor devices that record and retain a variety of sleep labs
patient physiological data via sensors.
Both units interface with a personal
computer to download and display the
collected data. Cricket retails for
approximately $1,800 and the more
sophisticated HMS 5000 retails for $10,000
to $25,000 (based on number of monitoring
channels).
NON-INVASIVE VENTILATORY
SUPPORT
BiPAP S/T Ventilatory Non-invasive bi-level device with automatic Home
Support System compensation for mask leaks and two
separate therapy modes. Designed
specifically for mask supplied ventilatory
support. Two models, retailing for $6,000
to $8,000.
BiPAP Hospital Ventilatory Non-invasive bi-level device that enhances Hospitals and
Support System functionality of BiPAP S/T for use in the post-acute
hospital environment. Two models, retailing facilities
for $5,000 to $8,000.
PATIENT MASKS
Face Masks Various face masks designed to provide a Home, hospitals
comfortable seal when used with the and post-acute
Company's CPAP and BiPAP products. The facilities
Company offers both reusable masks (for
home use) and disposable masks (for
hospital use) in a wide range of sizes.
Includes nasal sealing flap masks, as well
as the new GEL Mask and Monarch Mini Mask.
Air-filled cushion Disposable face masks used to deliver Hospitals
anesthesia masks anesthesia gases during surgical
procedures. Provide a uniform seal around
the patient's nose and mouth via a soft
plastic air-filled cushion. Nine sizes
manufactured for an exclusive marketer on
an OEM basis.
RESUSCITATION
BagEasy Disposable Self-inflating bag used to manually Hospitals and
Manual Resuscitator resuscitate patients who have stopped emergency
breathing and to sustain proper breathing settings
function for a short period of time. Three
models of the device currently offered.
</TABLE>
22
<PAGE>
Obstructive Sleep Apnea Products
Respironics believes it is the U.S. market share leader in OSA therapy
devices, with an approximate 50% market share. The Company's primary OSA
products are REMstar Choice and the BiPAP S Airway Management System and
related products such as masks, tubes, filters and headgear. Sales of OSA
products amounted to $38.7 million (68% of the Company's sales) for the six-
month period ended December 31, 1995, a 25% increase over the comparable
period in the prior year.
REMstar Choice is the Company's fifth generation CPAP device for the
treatment of OSA. REMstar Choice consists of a small, portable air
pressurization device, air pressure control, a cordless remote on-and-off
control and a mask worn by the patient at home during sleep. REMstar Choice
offers improved functional features compared to its predecessor devices,
including improved pressure stability, reduced operating noise and a smaller
design. The BiPAP S Airway Management System is used to treat severe OSA and
is useful in improving acceptance of therapy by patients who have difficulty
tolerating CPAP. The unit senses the patient's breathing cycles and adjusts
the pressure accordingly. See "--Non-invasive Ventilatory Support Products"
for a further description of the BiPAP devices.
The Company recently introduced its next-generation family of OSA products,
known as the "Great Performers" product line, with the first international
shipments commencing in July 1995. This new family of products will include
several products including CPAP, bi-level and clinical units. In February
1996, the Company received FDA clearance for one of these products, the Aria
CPAP system, and expects to begin domestic shipments of this device in spring
1996. The Aria CPAP system features built-in memory to record patient usage
data. The software necessary to extract this data from the Aria unit is
expected to be available in fall 1996. This software may require clearance to
market through the 510(k) process. This new family of products also includes a
CPAP device, known as Virtuoso, that utilizes innovative technology to monitor
the patient's airway and adjust output automatically in order to deliver the
appropriate pressure. Separate 510(k) filings are in process for Virtuoso and
other devices in the Great Performers series of products. There can be no
assurance that such 510(k) clearances for Virtuoso or any other products in
the Great Performers product line will be obtained in a timely manner or at
all. See "--Regulatory Matters." Products in the Great Performers product line
are being initially distributed solely in international markets until
regulatory clearance to market each product in the U.S. is obtained.
Respironics also manufactures devices related to the diagnosis and
monitoring of sleep and other respiratory-related disorders, which it obtained
through the acquisition of Vitalog in 1995. The Vitalog acquisition provides
the Company with access to technology and products complementary to its own,
particularly in the OSA product line and is part of the Company's strategic
effort to enter the diagnostic market. The Company believes that the Vitalog
acquisition will enhance its marketing efforts in the OSA area by expanding
the Company's presence in sleep labs and permitting the Company to sell
diagnostic equipment, which helps drive the market for the Company's
therapeutic devices.
Non-invasive Ventilatory Support Products
The Company believes it is the leading manufacturer and marketer of non-
invasive ventilatory support devices in the U.S. for individuals who require
ventilatory assistance but who are not dependent on a ventilator for
continuous life support. Non-invasive ventilatory support products represented
$14.9 million (26% of the Company's sales) in the six months ended December
31, 1995, a 27% increase over the comparable period in the prior year.
The Company's principal non-invasive ventilatory support product is the
BiPAP Ventilatory Support System. Introduced in December 1989, the BiPAP
Ventilatory Support System is a low-pressure, electrically-driven flow
generator with an electronic pressure control designed to augment patient
breathing by supplying pressurized air to the patient. The BiPAP Ventilatory
Support System was the first device for non-invasive use designed specifically
to compensate for mask leaks. BiPAP devices sense the
23
<PAGE>
patient's breathing and adjust their output to assist in inhalation and
exhalation. The BiPAP Ventilatory Support System compensates for mask leaks,
which often occur in the delivery of ventilatory support to the patient,
thereby providing what the Company believes is a more efficient and consistent
non-invasive therapy than competing ventilators.
The Company believes the BiPAP Ventilatory Support System has the potential
for increasing patient comfort because the BiPAP Ventilatory Support System
adapts to the patient's breathing cycles as opposed to requiring the patient
to adapt his breathing to the ventilator cycles and because it can be used
effectively with a patient mask rather than requiring intubation. The retail
price for a BiPAP unit also compares favorably to the cost of invasive
ventilators, which generally retail for $10,000 to $28,000.
In May 1992, the Company introduced the Hospital BiPAP Ventilatory Support
System, which includes accessories such as an airway pressure monitor, a
detachable control panel, a disposable circuit and a mounting stand, all of
which are designed to allow the BiPAP Ventilatory Support System to be used
more easily in the hospital environment.
The Company is supporting clinical trials that are investigating the
possible benefits of BiPAP therapy for different types of patient populations.
The results of recent studies have been favorable with respect to the use of
the BiPAP Ventilatory Support System for patients with chronic respiratory
deficiencies and patients with nocturnal breathing disorders who benefit from
ventilatory support. Applications being studied include use by patients
suffering from emphysema and other respiratory disorders, as well as other in-
hospital applications. The marketing of BiPAP Ventilatory Support Systems for
use in these patient populations may require additional clearances from the
FDA prior to marketing in the United States.
The Company also is currently incorporating Proportional Assist Ventilation
("PAV") into its line of BiPAP ventilatory support products. PAV is a mode of
ventilatory support that provides assistance in proportion to the needs of the
patient. The Company began sponsoring clinical trials investigating PAV in
1995. Application for regulatory clearance to market devices that include PAV,
which is required prior to the marketing of such products in the U.S., has not
yet been made. The PAV technology was obtained by the Company through a non-
exclusive licensing arrangement with the University of Manitoba in Winnipeg,
Canada.
Patient Mask Products
Patient masks represented $9.1 million (16% of the Company's sales) in the
six months ended December 31, 1995, an increase of 33% over the comparable
period in the prior year. The Company provides three types of patient masks:
(1) masks used with CPAP and BiPAP devices including nasal sealing flap masks,
the Monarch Mini Mask and, in the near future, the GEL Mask; (2) disposable
air-filled cushion anesthesia masks primarily for use during surgery; and (3)
disposable SealEasy and Circle Seal resuscitation masks for use in medical
emergencies. The Company's patient masks are designed to respond to the
increasing demand for single-use products, which reduce the potential for
cross-contamination among patients and also help to minimize the exposure of
medical personnel to infectious diseases, such as tuberculosis and pneumonia.
The Company believes that its nasal sealing flap mask was the first mask to
adequately seal on a patient's face for air delivery, thereby minimizing
patient discomfort and promoting increased patient compliance with prescribed
usage. The Company recently received 510(k) clearance to market the Monarch
Mini Mask and GEL Mask for use with its CPAP and BiPAP devices. The Monarch
Mini Mask is designed to enhance patient comfort with its small size and
unique placement on the patient's face; the GEL Mask utilizes a gel-like
cushion to create a comfortable mask seal around the contours of the face. The
Company's line of disposable air-filled cushion anesthesia masks utilizes a
very thin and pliable soft plastic air-filled cushion around the nose and
mouth, which provides a uniform seal to prevent leakage of the anesthetic
gases and helps ensure compliance with anesthesia gas exposure standards
imposed on hospitals by regulatory bodies.
24
<PAGE>
Resuscitation Products
The Company's other products consist of single-use resuscitation products.
The new BagEasy resuscitator represents a comprehensive redesign of an earlier
version of this product and includes significantly fewer components and
requires significantly fewer assembly steps than did the previous version. In
addition, the new BagEasy product includes features such as a flexible design
and an integral pressure valve that the Company believes distinguish it from
competitive products. A recent comparative study published in Respiratory Care
showed the BagEasy resuscitator to be the only manual resuscitator which met
all of the relevant standards established by the American Society for Testing
and Materials.
SALES, DISTRIBUTION AND MARKETING
The Company sells its products primarily to home care and hospital dealers.
These parties in turn resell and rent the Company's products to end users. The
Company's products reach its customers primarily through the Company's field
network, which consists of 11 sales management employees, 28 direct sales
representatives, 54 independent manufacturers' representatives and over 2,500
medical products distributors (also referred to as "dealers").
The Company manages its U.S. dealer network through a direct sales force and
independent manufacturers' representatives. The Company's U.S. sales
management team includes a Vice President of Sales and Marketing, a Director
of Sales and eight Regional Sales Managers. This team directs the activities
of 54 independent manufacturers' representatives and 26 direct sales
representatives and sales support specialists. In most areas of the U.S., the
hospital market is served by the direct sales representatives and the home
care market is served primarily by the independent manufacturers'
representatives.
The Company's international sales efforts are conducted currently through a
European General Manager, a European Sales Manager, a South American Sales
Manager and a Pacific Rim Sales Manager. The Company also has two direct sales
representatives in Europe. All of the Company's international sales employees
serve both the home care and hospital markets. The Company's international
sales consist primarily of BiPAP Ventilatory Support Systems, BiPAP S Airway
Management Systems, REMstar Choice, Aria and related accessories.
The Company's marketing organization is currently staffed with a Director of
Marketing and marketing-oriented Product Managers, who are assigned to each of
the Company's four principal product groups. The Product Managers stay abreast
of changes in the marketplace, with an emphasis on product use specifications,
features, price, promotions, education, training and distribution.
CUSTOMERS
The Company's primary customers are home care and hospital medical equipment
dealers. These dealers purchase products from the Company for resale or rental
to patients (in the case of home care dealers) or to hospitals (in the case of
hospital dealers). The Company's dealers, numbering over 2,500, range in size
from large publicly-held companies with several hundred branch locations, to
small, owner-operated companies with one location. Consolidation among these
dealers, particularly those specializing in home care products, has taken
place recently as many larger dealers have acquired smaller dealers. In
addition, the Company's two largest home care dealer customers, both of which
were publicly held and had branch locations throughout the U.S., merged in
August 1995. The Company expects that consolidation among home care dealers is
likely to continue.
Respironics is committed to quality and customer satisfaction and has
received the Zenith Award from the American Association of Respiratory Care
for three of the last five years. This award, which the Company last received
in December 1994, honors suppliers of respiratory medical products for
outstanding service to customers. Evaluation categories for the award include
product and service quality.
25
<PAGE>
RESEARCH AND DEVELOPMENT
The Company believes that its ability to identify product opportunities, to
respond to the needs of cardiopulmonary physicians and their patients in the
treatment of respiratory disorders and to incorporate the latest technological
innovations into its medical products has been and will continue to be
important to its success. The Company's research and development efforts are
focused on understanding the problems faced by cardiopulmonary physicians and
their patients' needs and on maintaining the Company's technological
leadership in its core product areas. The Company maintains both formal and
informal relationships with physician practitioners and researchers (including
sleep laboratories) to supplement these research and development efforts. The
Company's research and development efforts enable it to capitalize on
opportunities in the respiratory medical product market, through upgrading its
current products as well as developing new products.
The Company conducts substantially all of its research and development for
existing and potential new products in the U.S. As of December 31, 1995, the
Company employed approximately 85 engineers in such activities. The research
and development staff performs overall conceptual design work for all products
and the design work related to the manufacturing, engineering and tooling for
products manufactured by the Company. The Company spent approximately $4.1
million (7% of sales) during the six-month period ended December 31, 1995, up
from 5% of sales in fiscal year 1993, to support product enhancement and new
product development.
Several new product introductions took place during fiscal year 1995 and
early in fiscal year 1996 (including a redesigned BagEasy manual resuscitator,
new face masks, and part of the family of new OSA products), with additional
new product introductions expected to follow later in fiscal year 1996. By the
end of fiscal year 1996, the Company expects to have introduced additional new
products in both the Great Performers OSA product line and the non-invasive
ventilatory support product line. In some cases, initial distribution has
been, and will be, conducted in international markets until regulatory
clearance to market in the United States is obtained. See "--Regulatory
Matters."
MANUFACTURING
The Company generally seeks to perform all major assembly work in its own
manufacturing facilities. The Company currently operates manufacturing
facilities in the U.S., Hong Kong and the Peoples Republic of China. The
Company's corporate headquarters and domestic manufacturing operations are
owned by the Company and are located in a 116,000 square foot facility in
Murrysville, Pennsylvania, where the Company conducts final assembly of its
OSA, non-invasive ventilatory support and resuscitation products. The Company
also leases, on a month to month basis, a 22,000 square foot office facility
in Plum Borough, Pennsylvania approximately two miles from the existing
corporate headquarters facility. This leased facility currently houses the
Company's customer satisfaction and technical service groups.
In 1981, the Company began manufacturing operations in Hong Kong, where it
currently manufactures a portion of its patient mask products. The Company's
warehousing, assembly and administrative activities in Hong Kong are located
in an approximately 28,000 square foot light manufacturing complex in Kwun
Tong, Kowloon, Hong Kong. The premises are leased under a renewable agreement
expiring on April 30, 1997. The landlord of this space, Micro Electronics,
Ltd., is a shareholder of the Company.
The Company conducts the remainder of its patient mask manufacturing in a
facility in Shenzen City in the Peoples Republic of China, bordering Hong
Kong. The facility is leased and operated by the Company. The present
manufacturing space totals approximately 66,000 square feet. The facility is
located in a special economic zone (where the Company has been operating since
1987) that was established by the Peoples Republic of China in 1980 to induce
foreign investment.
26
<PAGE>
The Company believes that its present facilities in the United States, Hong
Kong and the Peoples Republic of China are suitable and adequate for its
current and presently anticipated future needs. While each facility is
currently extensively utilized, additional productive capacity is available
through a variety of means including, at the Murrysville site, augmenting the
current partial second shift work schedule. Rental space, which the Company
believes is readily available and reasonably priced near each current
location, could be utilized as well. The Company also owns approximately 20
acres of land adjacent to the 10 acre site on which the Murrysville facility
is located. Future expansion in Murrysville, if needed, will take place on
this 20 acre site.
The Company generally performs all major assembly work on all of its
products. It manufactures the plastic components for its patient mask products
and uses subcontractors to supply certain other components. The Company
believes that the raw materials for substantially all of its products are
readily available from a number of suppliers.
REGULATORY MATTERS
The Company's products are subject to regulation by, among other
governmental entities, the FDA and corresponding foreign agencies. The FDA
regulates the introduction, manufacture, advertising, labeling, packaging,
marketing and distribution of and recordkeeping for such products. In
manufacturing and marketing its products, the Company must comply with FDA
regulations and is subject to various other FDA recordkeeping requirements and
to inspections by the FDA. The testing for and preparation of required
applications can be expensive, and subsequent FDA review can be lengthy and
uncertain. Moreover, clearance or approval, if granted, can include
significant limitations on the indicated uses for which a product may be
marketed. Failure to comply with applicable FDA regulations can result in
fines, civil penalties, suspensions or revocation of clearances or approvals,
recalls or product seizures, operating restrictions or criminal penalties.
Delays in receipt of, or failure to receive, clearances or approvals for the
Company's products for which such clearances or approvals have not yet been
obtained would adversely affect the marketing of such products in the United
States and could adversely affect the results of future operations.
The Company must obtain FDA or foreign regulatory approval or clearance for
marketing the Company's new devices prior to their release. There are two
primary means by which the FDA permits a medical device to be marketed. A
manufacturer may seek clearance for the device by filing a 510(k) premarket
notification with the FDA. To obtain such clearance, the 510(k) premarket
notification must establish that the device is "substantially equivalent" to a
device that has been legally marketed or was marketed before May 28, 1976. The
manufacturer may not place the device into commercial distribution in the
United States until a substantial equivalence determination notice is issued
by the FDA. This notice may be issued within 90 days of submission, but
usually takes longer. The FDA, however, may determine that the proposed device
is not substantially equivalent, or require further information, such as
additional test data or clinical data, or require the Company to modify its
product labeling, before it will make a finding of substantial equivalence. In
addition, the FDA may inspect the Company's manufacturing facility before
issuing a notice of substantial equivalence and may delay or decline to issue
such notice until the facility is found to be in compliance with Good
Manufacturing Practice requirements. The process of obtaining FDA clearance of
a 510(k) premarket notification, including testing, preparation and subsequent
FDA review, can take a number of years and require the expenditure of
substantial resources.
If a manufacturer cannot establish to the FDA's satisfaction that a new
device is substantially equivalent to a legally marketed device, it will have
to seek approval to market the device through the premarket approval
application ("PMA") process. This process involves preclinical studies and
clinical trials. The process of completing clinical trials, submitting a PMA
and obtaining FDA approval takes a number of years and requires the
expenditure of substantial resources. In addition, there can be no
27
<PAGE>
assurance that the FDA will approve a PMA. The Company's export activities and
clinical investigations also are subject to the FDA's jurisdiction and
enforcement.
Foreign regulatory approvals vary widely depending on the country. In
January 1996, the Company received ISO 9001 certification from the
International Organization of Standards, a quality standards organization
based in Geneva, Switzerland. At the same time, the Company received
authorization, under the European Union's Medical Device Directives, to affix
the "CE Mark" to the Company's products marketed throughout the world. The
primary component of the certification process was an audit of the Company's
quality system conducted by an independent agency authorized to perform
conformity assessments under ISO guidelines and the Medical Device Directives.
Four FDA inspections have been conducted at the Company's facilities since
July 1, 1993. The first inspection took place from July 1993 through October
1993 at the Company's leased facility in Plum Borough, Pennsylvania where the
BagEasy product was then manufactured. A report on FDA Form 483 was issued by
the FDA investigators setting forth the results of the inspection, identifying
shortcomings with respect to systems procedures and documentation in the
BagEasy manufacturing process. Because making the modifications identified by
the FDA findings would have significantly delayed shipment to dealers and
customers and because the Company believed that a significant recall of
BagEasy products arising from an unrelated matter was necessary, the Company
discontinued the production and sale of the BagEasy product and recalled all
BagEasy products remaining in the field. The Company also responded to the
Form 483 findings with particular attention to implementing the required
improvements that were applicable to the systems, procedures and documentation
utilized at the Company's main facility in Murrysville, Pennsylvania. The
BagEasy recall is the only one of the five recalls since July 1, 1992 (all of
which have been voluntary) that resulted in a material adverse effect on the
Company's results of operations or financial condition.
The second inspection took place at various times between May 1994 and
August 1994 at the Murrysville facility. In late August 1994, the FDA
investigators issued a report on an FDA Form 483 setting forth their
observations from this inspection. The Company responded to these findings in
September 1994. On December 22, 1994 the Company received a warning letter
from the FDA relating to the FDA's August 1994 Form 483 findings and the
Company's response thereto. A "warning letter" is a statement issued by the
FDA that significant violations have occurred and that the agency is prepared
to take enforcement action if corrective measures are not taken. In the
warning letter, the FDA raised issues relating to: (i) alleged shortcomings in
the Company's complaint processing procedures, (ii) the Company's alleged
failure to file certain MDRs and (iii) the Company's alleged failure to obtain
510(k) premarket notification clearances that the FDA indicated were necessary
for certain features of the Company's BiPAP systems and for certain claims
regarding that product's use. Each of these issues is discussed below.
Complaint Procedure. The FDA stated that the Company's complaint records did
not comply with Good Manufacturing Practice regulations. The Company has
revised its procedures and complaint recordkeeping to address this issue. In
addition, the Company's complaint processing system has been automated. Based
on the results of a follow-up investigation described below, the Company
believes that this aspect of the FDA's warning letter has been resolved.
Medical Device Reports. An MDR is required to be filed if a manufacturer
receives a report that (i) a death or serious injury has occurred and its
products may have caused or contributed to the death or serious injury or (ii)
its product has malfunctioned and the product would be likely to cause or
contribute to a death or serious injury if the malfunction were to recur. The
FDA stated in its warning letter that the Company had not filed an MDR for
what the FDA believed to be a reportable malfunction. In response,
28
<PAGE>
the Company has filed MDRs with respect to certain malfunctions which the FDA
referred to at the time of its 1994 inspections, and the Company has also
changed certain procedures with respect to the determination of when an MDR
will be filed. Based on the results of a follow-up investigation described
below, the Company believes that this aspect of the FDA's warning letter has
been resolved.
510(k) BiPAP Ventilation Issues. In 1987, the Company submitted to the FDA
its original 510(k) premarket notification for its bi-level ventilatory
support device. This 510(k) notification contained an intended use statement
indicating that the device was a non-continuous ventilator "for the treatment
of various pulmonary diseases." This notification identified the Bird(R) Mark
7(R) respirator as the predicate device. The FDA cleared this 510(k)
notification in 1987. The Company believes that it has all 510(k) premarket
notification clearances required for the uses for which it markets its BiPAP
ventilatory products.
The concerns cited in the FDA warning letter with respect to the Company's
510(k) premarket notification clearances related solely to its BiPAP systems
and involved allegations that the Company had modified the previously cleared
devices so as to require additional clearances and that the Company was
marketing the devices for uses that were not within the scope of its 510(k)
premarket notification clearances. In connection with the December 1994
warning letter, some FDA officials have advised the Company that the existing
510(k) clearances for BiPAP are limited to the treatment of OSA in adults.
Based on the language in the Company's 1987 510(k) notification that was
cleared by the FDA, the Company disagrees with this position.
Since receiving the warning letter, in an effort to cooperate with the FDA's
current requests, the Company has filed with the FDA additional 510(k)
premarket notifications with respect to the features that were cited in the
warning letter and certain uses beyond adult OSA, in each case indicating that
the application was filed without prejudice to the Company's position that no
additional filing was required. The FDA has reviewed the 510(k) applications
filed and has requested additional information. The Company has provided, and
is currently preparing, responses to the FDA's requests. There can be no
assurance that the FDA will clear any of the 510(k) premarket notifications or
that the clearances, if obtained, will be obtained in a timely manner, nor can
there be any assurance that the FDA will not take enforcement action with
respect to the prior or continued marketing of the devices for certain
indications or with certain features.
Respironics is cooperating with the FDA in attempting to resolve the issues
which gave rise to the warning letter. Among other things, it has improved its
record keeping and complaint procedures and filed MDRs and 510(k) premarket
notification requests even where the Company believed such filings were not
required. The Company believes that it is in substantial compliance with FDA
requirements relating to its products and believes that the existing 510(k)
clearances for BiPAP encompass claims in addition to the treatment of OSA in
adults and the technical features cited in the FDA warning letter. However,
the Company does not know what, if any, action the FDA ultimately will take in
response to the Company's responses and additional 510(k) filings relating to
the warning letter. The Company does not believe that there is likely to be
any interruption of its business as a result of the issues raised in the
December 1994 warning letter, but there can be no assurance that such will not
occur or that the FDA will not take enforcement action.
The third FDA inspection took place at the Murrysville facility in January
1995. A report on a Form 483 was issued by the FDA investigator setting forth
the results of the inspection, which had focused on a voluntary recall
conducted by the Company. The Form 483 also reiterated the FDA's position
relative to the 510(k) clearances for BiPAP. The Company responded to the Form
483 findings in February 1995.
The fourth FDA inspection took place at the Murrysville facility in May
1995. A report on a Form 483 was issued by the FDA investigators setting forth
the results of the inspection, which had focused on the Company's revised
systems complaints and MDRs. Revisions had been made to these systems as
described above. The Form 483 issued for this inspection did not refer to MDRs
or complaint handling, but contained only the FDA's reiteration of its
position relative to the 510(k) clearances for BiPAP. The Company responded to
the Form 483 findings in June 1995.
29
<PAGE>
The Company recently has received 510(k) clearance for three products; a
CPAP device and two masks. In addition to the BiPAP 510(k) notifications
currently pending, the Company plans to file additional 510(k) notifications
as part of its continuing product development process.
THIRD PARTY REIMBURSEMENT
The cost of a significant portion of medical care in the United States is
funded by government and private insurance programs, such as Medicare,
Medicaid and corporate health insurance programs including health maintenance
organizations and managed care organizations. The Company's future results of
operations and financial condition could be negatively affected by adverse
changes made in the reimbursement policies for medical products under these
insurance programs. If such changes were to occur, the ability of the
Company's customers (medical product distributors and dealers) to obtain
adequate reimbursement for the resale or rental of the Company's products
could be reduced. In recent years, limitations imposed on the levels of
reimbursement by both government and private insurance programs have become
more prevalent.
The Company has obtained "procedure codes" for its home care products from
the Health Care Financing Administration ("HCFA"). These procedure codes
enhance the ability of medical product distributors and dealers to obtain
reimbursement for providing products to patients covered by Medicare. In
addition, many private insurance programs also use the HCFA procedure code
system. However, reimbursement levels can be reduced after a procedure code
has been established, as was the case in January 1994 when the reimbursement
level for all nasal CPAP systems was reduced.
The amount of reimbursement that a hospital can obtain under the Medicare
diagnosis related group ("DRG") payment system for utilizing the Company's
products in treating patients is a primary determinant of the revenue that can
be realized by medical product distributors and dealers who resell or rent the
Company's hospital products. Many private insurance programs also utilize the
Medicare DRG system. The various uses of the Company's hospital products to
treat patients are provided within the DRG system. The levels of reimbursement
under the DRG system are also subject to review and change.
LEGAL PROCEEDINGS
Patent Litigation. ResCare Limited, an Australian corporation ("ResCare")
and a subsidiary of ResMed, Inc. ("ResMed"), filed suit in Australia (the
"Australian suit") against the Company's Australian distributor in 1992,
alleging that the Company's CPAP products then being sold by such distributor
in Australia infringed upon an Australian patent (the "Australian Patent")
embodying a substantial part of ResCare's CPAP technology. After trial, the
Australian trial court held that the Company's products infringed the
Australian Patent (which the Court also held to be valid). This decision was
appealed, and in May 1994 the Australian Court of Appeals reversed the
decision of the trial court, declaring the Australian Patent invalid. This
decision also nullified the trial court's finding that the Company's products
infringed upon the Australian Patent. In October 1994, the Supreme Court of
Australia refused to accept an appeal of the decision of the Court of Appeals.
No further appeals can be made by ResCare with respect to the decision of the
Australian Court of Appeals. The Company now is seeking to collect from
ResCare that portion of the Company's expenses in pursuing the Australian suit
which the Company believes it is entitled to recover under applicable
Australian law.
On January 9, 1995 ResCare filed an action (the "California suit") against
the Company in the United States District Court for the Southern District of
California alleging that in the manufacture and sale in the U.S. of nasal
masks and CPAP systems and components the Company infringes three U.S. patents
(the "ResCare Patents"), two of which are owned by and one of which is
licensed to ResCare. One of the three ResCare Patents was filed in the U.S.
shortly after the Australian Patent was issued and most of its claims are the
same as or similar to the Australian Patent. The other two patents involved in
the California suit
30
<PAGE>
deal with mask applications and with a "ramp" feature of ResCare's CPAP
devices. In its complaint, ResCare seeks preliminary and permanent injunctive
relief, an accounting for damages and an award of three times actual damages
because of the Company's alleged actual knowledge of the alleged infringement.
On February 1, 1995 the Company filed an action in the United States District
Court for the Western District of Pennsylvania against ResCare seeking a
declaratory judgment that the three ResCare Patents are either invalid or
unenforceable or that the Company does not infringe the patents. The Company
also filed a motion in the United States District Court for the Southern
District of California seeking to transfer the California suit to the United
States District Court for the Western District of Pennsylvania. This motion
was granted and both cases have been consolidated in Pittsburgh, Pennsylvania.
Discovery has been underway since early spring 1995.
In its answer to ResCare's complaint the Company denied, in all material
respects, the allegations of the complaint. It is the Company's belief, based
upon its investigation and discovery to date and upon discussions with its
counsel, that the ResCare Patents are invalid or unenforceable and that, even
if they are valid and enforceable, none of its products infringe any of the
ResCare Patents. The Company intends vigorously to defend and pursue this
litigation and strongly believes that the outcome should be favorable to it.
Nevertheless, it is possible that the ResCare patents could be held valid and
the Company's OSA products could be found to infringe the ResCare patents. If
that were to happen, the Company may be required to pay damages and either
would need to redesign its products so as not to infringe or would need to
obtain a license to use the ResCare Patents, any of which could have a
material adverse effect on the Company's financial condition and results of
operations. The sale of the products which ResCare alleges infringe the
ResCare Patents constitute approximately one-half of the Company's sales of
OSA products.
Other Matters. The Company is, as a normal part of its business operations,
a party to other legal proceedings in addition to those described above. Legal
counsel has been retained for each proceeding and none of these proceedings is
expected to have a material adverse impact on the Company's results of
operations or financial condition. See "--Regulatory Matters" for information
concerning FDA matters.
COMPETITION
The Company believes that the principal competitive factors in all of its
markets are product and service performance and innovation. Efficient
distribution and competitive price are also very important factors for its
more mature products. In the case of a number of the Company's and its
competitors' products, patent protection is becoming more prevalent and of
increasing competitive importance. The Company competes on a product-by-
product basis with various other companies, some of which have significantly
greater financial and marketing resources and broader product lines.
The Company believes that it has the leading position in the U.S. market for
home care devices for the treatment of OSA. However, other manufacturers,
including other larger and more experienced manufacturers of home health care
products, have been in the market and the Company expects that competition
will increase. In its major market segments, the Company competes with three
principal competitors, Nellcor Puritan-Bennett ("Nellcor"), Healthdyne
Technologies ("Healthdyne") and ResMed. Nellcor, which is the Company's
largest major competitor and has the largest financial resources of the
Company's competitors, offers an array of products which compete with all of
the Company's products. Healthdyne is the primary competitor for the Company's
CPAP units and competes with the Company in the non-invasive ventilatory
support market as well. ResMed competes with the Company in the OSA market,
principally through its subsidiary, ResCare. The manual resuscitator market,
which the Company recently reentered with its new version of BagEasy, is a
very competitive, price-sensitive market.
PATENTS, TRADEMARKS AND LICENSES
The Company seeks patent protection for its products through the acquisition
of patents and exclusive licensing arrangements. In addition, the Company
defends its patents when infringed by other
31
<PAGE>
companies. The Company currently has approximately 20 U.S. and foreign patents
and 40 additional U.S. and foreign patent applications pending.
The Company owns the proprietary rights to most of its current products,
including patents on the BiPAP Airway Management System, BiPAP Ventilatory
Support System, SealEasy, components of its nasal sealing flap mask and other
valve and mask related accessories.
In July 1995, the Company received additional method and technical patent
protection related to its BiPAP devices. The method patent protection applies
to the use of bi-level pressure to treat OSA. The technical patent protection
covers the manner in which the device uses flow signals to trigger and apply
pressure.
The Company currently has approximately 50 registered U.S. and foreign
trademarks and 90 additional U.S. and foreign trademark applications have been
filed.
EMPLOYEES
As of December 31, 1995, the Company had 1,116 employees, including
approximately 244 hourly employees in the United States and 454 in Hong Kong
and the Peoples Republic of China. None of the Company's employees is covered
by collective bargaining agreements. The Company considers its labor relations
to be good and has never suffered a work stoppage as a result of a labor
conflict.
32
<PAGE>
MANAGEMENT
The executive officers and directors of the Company are listed below,
followed by a brief description of their business experience and certain other
information. The Company's Board of Directors is divided into three classes,
with each class of directors serving a term of three years.
<TABLE>
<CAPTION>
NAME AGE POSITION WITH THE COMPANY
---- --- ------------------------------
<S> <C> <C>
Gerald E. McGinnis 61 Chairman of the Board
Dennis S. Meteny 42 President, Chief Executive
Officer and Director
Ronald J. Zdrojkowski, Ph.D. 53 Vice President -- Research and
Development
Robert D. Crouch 48 Vice President -- Sales and
Marketing
Robert A. Oates 52 Vice President -- Engineering
Daniel J. Bevevino 36 Controller and Chief Financial
Officer
Daniel P. Barry 48 Director
Douglas A. Cotter, Ph.D. 52 Director
James H. Hardie 66 Director
Joseph C. Lawyer 50 Director
George J. Magovern, M.D. 72 Director
Bernard Shou-Chung Zau 58 Director
</TABLE>
Mr. McGinnis has been a director of the Company since 1977 and has been
Chairman of the Board since November 1994. Mr. McGinnis is also an employee of
the Company, primarily responsible for coordination of strategic planning as
well as Board liaison with senior management of the Company. Mr. McGinnis was
the Chief Executive Officer of the Company from 1977 until November 1994 and
was its President from 1984 until November 1994. Prior to 1977, Mr. McGinnis
founded and was President of Lanz Medical Products Corporation, the
predecessor of the Company ("Lanz"). Prior to founding Lanz, Mr. McGinnis
worked at two Pittsburgh hospitals serving in various research capacities and
at Westinghouse Electric Corporation in the Bio-Engineering Department.
Mr. Meteny has been a director of the Company since January 1986 and has
been President and Chief Executive Officer since November 1994. Mr. Meteny was
the Company's Executive Vice President and Chief Operating Officer from August
1992 until November 1994. He was Vice President--General Manager and Chief
Financial Officer of the Company from January 1988 through August 1992 and was
Vice President--Finance and Accounting from 1984 through January 1988. For
eight years prior to joining the Company he was employed as an accountant in
various auditing capacities by Ernst & Young LLP.
Dr. Zdrojkowski has been Vice President--Research and Development since late
1990. Dr. Zdrojkowski was Vice President--Engineering for the Company from
1987 to 1990 and also held that position from 1977 to 1985. From 1985 to 1987
he was Product Development Manager. Dr. Zdrojkowski joined the Company in 1977
and has worked on the design, development and manufacturing of most of the
Company's products. Prior to joining the Company, he worked as a consultant
for various companies, assisting in the design of new medical products.
Mr. Crouch has been Vice President--Sales and Marketing of the Company since
May 1989. He joined the Company as Director of Sales and Marketing in January
1989. From 1986 to 1989, Mr. Crouch worked as a consultant for various
companies on administrative and governmental affairs issues. From 1985 to
1986, he was employed by Cryogenic Associates, serving as Executive Vice
President and later President. From 1983 to 1985, Mr. Crouch was President,
Chief Executive Officer and Chairman of the Board of Beta Med Pharmaceuticals,
Inc., a start-up manufacturer of parenteral products.
33
<PAGE>
Mr. Oates has been Vice President--Engineering of the Company since July
1992. From 1982 to July 1992, he was employed by Westinghouse Electric
Corporation's Science & Technology Center, serving as the Manager of
Communication Systems, Sensor Development and Electro-optic Systems.
Mr. Bevevino has been Chief Financial Officer and Controller of the Company
since November 1994. Mr. Bevevino joined the Company in 1988, serving as
Manager of Cost Accounting until 1990 when he was elected Controller. Prior to
joining the Company, Mr. Bevevino worked for five years as an accountant in
various auditing capacities at Ernst & Young LLP.
Mr. Barry has been a director of the Company since August 1995. Currently he
is Vice Chairman of AMSCO International, Inc. ("AMSCO"), a manufacturer of
surgical sterilization equipment. He served as President and Chief Executive
Officer of AMSCO from October 1994 through July 1995 and Senior Vice
President--Financial and Planning (CFO) of AMSCO from April 1993 to October
1994. Prior thereto he served in various executive and consulting capacities
with AMSCO since 1981; he has been a director of AMSCO since 1991. He is also
a director of Tollgrade Communications, Inc., a designer and marketer of
proprietary products used by telephone companies in their diagnosis of lines
containing both copper and fiber optics.
Dr. Cotter has been a director of the Company since February 1989. Since
1985 he has been President of Healthcare Decisions, Inc., a Massachusetts
health care and biotechnology consulting firm specializing in corporate
development, strategic planning and acquisitions. For nineteen years prior to
joining Healthcare Decisions he was employed by Corning Glass Works, where he
held various management positions in research, product development and
clinical information systems. Dr. Cotter is also a director of Applied
Microbiology, Inc., a developer, manufacturer and marketer of antimicrobial
food preservatives and specialty medical food products.
Mr. Hardie has been a director of the Company since November 1991. He is a
lawyer and a partner of Reed Smith Shaw & McClay, a law firm with principal
offices in Pittsburgh, Washington and Philadelphia, which since 1988 has
performed legal services for the Company. Mr. Hardie has been a partner of
that firm since 1962. He is a Director of Access Corporation, a marketer and
developer of document and image handling systems and related software. He is
also a director of a number of other corporations the securities of which are
not publicly traded.
Mr. Lawyer has been a director since November 1994. Since 1988, he has been
President and Chief Executive Officer and a Director of Chatwins Group, Inc.
("CGI"), headquartered in Pittsburgh, Pennsylvania, which designs,
manufactures and markets a broad range of fabricated and machined parts and
products, in a variety of industries primarily to original equipment
manufacturers. From 1986 to 1988 he was President and Chief Executive Officer
and a Director of CP Industries, a predecessor company of CGI. Prior thereto,
he held various operations, marketing, sales, finance and strategic planning
positions for U.S. Steel Corporation for 17 years.
Dr. Magovern has been a director of the Company since 1983 and was Chairman
of the Board from November 1986 until November 1994. Since 1968 Dr. Magovern
has been director of the Department of Surgery, Allegheny General Hospital, a
736-bed, acute care teaching hospital in Pittsburgh. He has been affiliated
with Cardio-Thoracic Surgical Associates, Inc., a professional corporation,
since 1970. He has been a Clinical Associate Professor of Surgery at the
University of Pittsburgh School of Medicine and is currently a Professor of
Surgery at the Medical College of Pennsylvania. Dr. Magovern has participated
in the development of the application of bio-engineering to cardiac and
thoracic surgery at Allegheny General Hospital.
Mr. Zau has been a director of the Company since July 1984. Since prior to
1984, Mr. Zau has been the Managing Director of Micro Electronics, Ltd., a
privately-held manufacturer of electrical components located in Hong Kong and
a shareholder in the Company. He currently serves as director of several other
privately-held entities in Hong Kong. He resides in Hong Kong.
34
<PAGE>
PRINCIPAL AND SELLING STOCKHOLDERS
The following table shows the number of shares of Common Stock beneficially
owned by each director of the Company, the Chief Executive Officer and the
four other executive officers, and by all directors and executive officers of
the Company as a group, as of March 25, 1996. It also shows the number of
shares beneficially owned and to be sold by each Selling Stockholder.
Management of the Company does not know of any other person who beneficially
owned as of such date more than five percent of the outstanding shares of the
Company's Common Stock. As used herein, "beneficial ownership" means the sole
or shared power to vote, or to direct the voting of, a security, or the sole
or shared investment power with respect to a security (i.e., the power to
dispose of, or to direct the disposition of, a security). A person is deemed,
as of any date, to have "beneficial ownership" of any security that the person
has the right to acquire within 60 days after that date. Except as otherwise
indicated, each of the persons listed has sole investment and voting power
with respect to the shares indicated.
<TABLE>
<CAPTION>
SHARES SHARES TO BE
BENEFICIALLY BENEFICIALLY
OWNED PRIOR NUMBER OF OWNED AFTER
TO OFFERING SHARES OFFERING(1)
NAME OF ----------------- BEING -----------------
BENEFICIAL OWNER NUMBER PERCENT OFFERED NUMBER PERCENT
----------------- --------- ------- --------- --------- -------
<S> <C> <C> <C> <C> <C>
Daniel P. Barry.................. 0 0.0% 0 0 0.0%
Daniel J. Bevevino (2)........... 33,600 0.2 0 33,600 0.2
Douglas A. Cotter, Ph.D. (3)..... 26,356 0.2 0 26,356 0.1
Robert D. Crouch (4)............. 280,000 1.6 0 280,000 1.5
James H. Hardie (3), (5)......... 25,616 0.2 5,000 20,616 0.1
Joseph C. Lawyer (3), (6)........ 1,272 0.0 0 1,272 0.0
George J. Magovern, M.D. (3),
(7).............................. 922,409 5.5 300,000 622,409 3.3
Gerald E. McGinnis (8)........... 1,426,784 8.3 500,000 926,784 4.8
Dennis S. Meteny (9)............. 422,568 2.5 40,000 382,568 2.0
Robert M. Oates (10)............. 29,750 0.2 2,117 27,633 0.2
Bernard Shou-Chung Zau (3)....... 369,032 2.2 40,000 329,032 1.7
Ronald J. Zdrojkowski, Ph.D...... 753,328 4.5 117,355 635,973 3.4
All of the directors and
executive officers
as a group (12 persons)......... 4,290,715 24.3 1,004,472 3,286,243 16.7
Former shareholders of Vitalog
(11)............................. 85,094 0.5 25,528 59,566 0.3
</TABLE>
- --------
(1) Assumes no exercise of the Underwriters' over-allotment option. If the
over-allotment option is exercised in full, the percentage ownership of
Dr. Magovern and Messrs. Hardie, McGinnis, Meteny, Oates, Zau and
Zdrojkowski would be 3.2%, 0.1%, 4.3%, 2.0%, 0.1%, 1.7% and 3.3%,
respectively.
(2) Includes 33,600 shares subject to currently exercisable stock options
granted under the Company's stock option plans.
(3) Includes shares subject to currently exercisable stock options granted
under the Company's Non-Employee Directors' Stock Option Plan in the
following amounts: Dr. Cotter, 24,016 shares; Mr. Hardie, 12,016 shares;
Mr. Lawyer, 1,272 shares; Dr. Magovern, 24,016 shares; and Mr. Zau, 24,016
shares.
(4) Includes 200,000 shares subject to currently exercisable stock options
granted under the Company's stock option plans.
(5) Includes 13,000 shares of the Company's Common Stock held by a partnership
in which Mr. Hardie is the general partner. Does not include 14,000 shares
owned by Mr. Hardie's wife, as to which he disclaims any beneficial
ownership.
(6) Does not include 550 shares held by Mr. Lawyer's wife, as to which he
disclaims beneficial ownership.
35
<PAGE>
(7) Includes 801,383 shares held jointly with Dr. Magovern's wife, as to which
voting and investment power is shared, 33,500 shares held by the Magovern
Grandchildren's Trust of which Dr. Magovern and his wife are the trustees,
55,000 shares held by the Magovern Equalization Trust of which Dr.
Magovern and his wife are the trustees and 8,510 shares held by the
Magovern Family Foundation Trust of which Dr. Magovern and his wife are
the Trustees. Dr. Magovern's business address is 320 E. North Ave.,
Pittsburgh, PA 15212. Does not include 117,647 shares, all or part of
which Dr. Magovern has the right to acquire in exchange for interests in
the partnership which owns such shares.
(8) Includes 992,384 shares held jointly with Mr. McGinnis' wife, as to which
voting and investment power is shared. Also includes 385,000 shares which
would be outstanding upon the exercise of currently exercisable stock
options granted to Mr. McGinnis. Also includes 34,400 shares held in the
Gerald E. McGinnis Charitable Trust. Does not include 106,000 shares held
by Mr. McGinnis' wife, as to which Mr. McGinnis disclaims beneficial
ownership. Mr. McGinnis' business address is 1001 Murry Ridge Drive,
Murrysville, PA 15668.
(9) Includes 184,000 shares held jointly with Mr. Meteny's wife, as to which
voting and investment power is shared, and 4,000 shares held by Mr.
Meteny's minor children, as to which he controls voting and investment
power. Also includes 112,000 shares subject to currently exercisable stock
options granted under the Company's stock option plans.
(10) Includes 28,750 shares subject to currently exercisable stock options
granted under the Company's stock option plans.
(11) Zeala Dunlop-Miles, Laughton E. Miles and a trust of which they are the
trustees, and a maximum of five other persons, all former Vitalog
shareholders, are selling an aggregate of 25,528 shares of the 85,094
shares of Common Stock they received in the acquisition of Vitalog by the
Company. None of the former Vitalog shareholders owns more than 1% of the
outstanding shares of Common Stock.
The information presented is based upon the knowledge of management and, in
the case of the named individuals, upon information furnished by them.
36
<PAGE>
UNDERWRITING
Subject to the terms and the conditions of the Underwriting Agreement, the
Underwriters named below (the "Underwriters"), through their Representatives,
Alex. Brown & Sons Incorporated, Cowen & Company and Parker/Hunter
Incorporated, have severally agreed to purchase from the Company and the
Selling Stockholders the following respective numbers of shares of Common
Stock at the public offering price less the underwriting discounts and
commissions set forth on the cover page of this Prospectus:
<TABLE>
<CAPTION>
NUMBER OF
UNDERWRITER SHARES
----------- ---------
<S> <C>
Alex. Brown & Sons Incorporated....................................... 743,334
Cowen & Company....................................................... 743,333
Parker/Hunter Incorporated............................................ 743,333
Dillon, Read & Co. Inc................................................ 120,000
Smith Barney Inc...................................................... 120,000
Arthurs, Lestrange & Company Incorporated............................. 80,000
Dain Bosworth Incorporated............................................ 80,000
McDonald & Company Securities, Inc.................................... 80,000
Rodman & Renshaw, Inc................................................. 80,000
Sutro & Co. Incorporated.............................................. 80,000
Tucker Anthony Incorporated........................................... 80,000
Wheat, First Securities, Inc.......................................... 80,000
---------
Total............................................................ 3,030,000
=========
</TABLE>
The Underwriting Agreement provides that the obligations of the Underwriters
are subject to certain conditions precedent and that the Underwriters will
purchase all shares of the Common Stock offered hereby if any such shares are
purchased.
The Company and the Selling Stockholders have been advised by the
Representatives of the Underwriters that the Underwriters propose to offer the
shares of Common Stock to the public at the public offering price set forth on
the cover page of this Prospectus and to certain dealers at such price less a
concession not in excess of $0.62 per share. The Underwriters may allow, and
such dealers may reallow, a concession not in excess of $0.10 per share to
certain other dealers. After the public offering, the offering price and other
selling terms may be changed by the Representatives of the Underwriters.
The Company and two Selling Stockholders have granted to the Underwriters an
option, exercisable not later than 30 days after the date of this Prospectus,
to purchase up to 454,500 additional shares of Common Stock at the public
offering price less the underwriting discounts and commissions set forth on
the cover page of this Prospectus. To the extent that the Underwriters
exercise such option, each of the Underwriters will have a firm commitment to
purchase approximately the same percentage thereof that the number of shares
of Common Stock to be purchased by it shown in the above table bears to
3,030,000, and the Company and such Selling Stockholders will be obligated,
pursuant to the option, to sell such shares to the Underwriters. The
Underwriters may exercise such option only to cover over-allotments made in
connection with the sale of Common Stock offered hereby. If purchased, the
Underwriters will offer such additional shares on the same terms as those on
which the 3,030,000 shares are being offered.
In connection with this offering, certain Underwriters and selling group
members (if any) or their respective affiliates who are qualified registered
market makers on the Nasdaq National Market may engage in passive market
making on Nasdaq in accordance with Rule 10b-6A under the Exchange Act during
the two business day period before the commencement of the offers of sales of
the Common Stock. The passive market making transactions must comply with
applicable volume and price limits and be identified as such. In general, a
passive market maker may display its bid at a price not in excess of the
highest independent bid for such security; if all independent bids are lowered
below the passive market maker's bid, however, such bid must then be lowered
when certain purchase limits are exceeded.
37
<PAGE>
The Company and the Selling Stockholders have agreed to indemnify the
Underwriters against certain liabilities, including liabilities under the
Securities Act.
The Company, its officers and directors, and certain Selling Stockholders,
beneficially owning in the aggregate approximately 3,300,000 shares of Common
Stock, have agreed not to offer, sell or otherwise dispose of any such Common
Stock for a period of 90 days after the date of this Prospectus without the
prior written consent of Alex. Brown & Sons Incorporated, on behalf of the
Representatives of the Underwriters.
LEGAL MATTERS
Legal matters in connection with the sale of the shares offered by this
Prospectus are being passed upon for the Company and the Selling Stockholders
by Reed Smith Shaw & McClay, James H. Reed Building, 435 Sixth Avenue,
Pittsburgh, Pennsylvania 15219. James H. Hardie, a director of the Company and
a Selling Stockholder, is a partner of Reed Smith Shaw & McClay and is the
beneficial owner of 25,616 shares of Common Stock. Certain legal matters in
connection with the sale of the shares offered by this Prospectus are being
passed upon for the Underwriters by Ropes & Gray, One International Place,
Boston, Massachusetts 02110.
EXPERT
The consolidated financial statements of the Company at June 30, 1995 and
1994, and for each of the three years in the period ended June 30, 1995,
appearing in this Prospectus and Registration Statement have been audited by
Ernst & Young LLP, independent auditors, as set forth in their reports thereon
appearing elsewhere herein, and are included in reliance upon such reports
given upon the authority of such firm as experts in accounting and auditing.
INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE
The following documents heretofore filed with the Commission by the Company
are incorporated in this Prospectus by reference and made a part hereof:
(1) The Company's Annual Report on Form 10-K for the fiscal year ended June
30, 1995, filed pursuant to Section 13 of the Exchange Act.
(2) The Company's Quarterly Reports on Form 10-Q for the quarters ended
September 30, 1995 and December 31, 1995, filed pursuant to Section 13
of the Exchange Act.
(3) The description of the Common Stock set forth in the Company's
Registration Statement on Form 8-A, effective May 12, 1988, including
all reports updating such description.
Each document or report subsequently filed by the Company with the
Commission pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act
prior to the termination of this offering shall be deemed to be incorporated
by reference into this Prospectus and to be a part of this Prospectus from the
date of filing of such document or report. Any statement contained herein, or
in a document all or a portion of which is incorporated or deemed to be
incorporated by reference herein, shall be deemed to be modified or superseded
for purposes of this Prospectus to the extent that a statement contained
herein or in any other subsequently filed document which also is or is deemed
to be incorporated by reference herein modifies or supersedes such statement.
Any such statement so modified or superseded shall not be deemed, except as so
modified or superseded, to constitute a part of this Prospectus.
The Company will provide without charge to any person to whom this
Prospectus is delivered, on the written or oral request of such person, a copy
of any or all of the foregoing documents incorporated by reference, other than
exhibits to such documents, unless such exhibits are specifically incorporated
by reference into such documents. Written requests should be directed to:
Investor Relations, Respironics, Inc., 1001 Murry Ridge Drive, Murrysville, PA
15668. Telephone requests may be directed to the Company at (412) 733-0209.
38
<PAGE>
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
<TABLE>
<S> <C>
Report of Independent Auditors.............................................. F-2
Consolidated Balance Sheets................................................. F-3
Consolidated Statements of Operations....................................... F-4
Consolidated Statements of Cash Flows....................................... F-5
Consolidated Statements of Shareholders' Equity............................. F-6
Notes to Consolidated Financial Statements.................................. F-7
</TABLE>
F-1
<PAGE>
REPORT OF INDEPENDENT AUDITORS
Board of Directors
Respironics, Inc.
We have audited the accompanying consolidated balance sheets of Respironics,
Inc. and subsidiaries as of June 30, 1995 and 1994, and the related
consolidated statements of operations, shareholders' equity, and cash flows
for each of the three years in the period ended June 30, 1995. These financial
statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of
material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis
for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the consolidated financial position of Respironics,
Inc. and subsidiaries at June 30, 1995 and 1994, and the consolidated results
of their operations and their cash flows for each of the three years in the
period ended June 30, 1995, in conformity with generally accepted accounting
principles.
As discussed in Note A to the consolidated financial statements, the Company
changed its method of accounting for income taxes in 1994.
Ernst & Young LLP
Pittsburgh, Pennsylvania
September 11, 1995
F-2
<PAGE>
RESPIRONICS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
<TABLE>
<CAPTION>
JUNE 30 DECEMBER 31
1994 1995 1995
----------- ----------- -----------
(UNAUDITED)
<S> <C> <C> <C>
ASSETS
CURRENT ASSETS
Cash and short-term investments...... $12,384,054 $16,126,904 $ 9,792,908
Trade accounts receivable, less
allowance for doubtful accounts of
$525,000, $700,000 and $850,000..... 15,011,285 19,448,187 25,026,073
Refundable income taxes.............. 1,787,265 -0- -0-
Inventories.......................... 7,833,755 13,136,664 17,300,722
Prepaid expenses and other........... 1,168,167 1,951,358 2,338,969
Deferred income tax benefits......... 2,021,776 2,200,595 2,200,595
----------- ----------- -----------
TOTAL CURRENT ASSETS............. 40,206,302 52,863,708 56,659,267
PROPERTY, PLANT AND EQUIPMENT
Land................................. 2,417,334 2,589,117 2,773,246
Building............................. 7,713,405 8,674,675 8,779,610
Machinery and equipment.............. 10,849,230 14,155,510 15,762,719
Furniture and office equipment....... 7,240,447 9,394,000 10,681,202
Leasehold improvements............... 519,744 577,175 979,717
----------- ----------- -----------
28,740,160 35,390,477 38,976,494
Less allowances for depreciation and
amortization........................ 11,929,911 15,443,041 17,207,404
----------- ----------- -----------
16,810,249 19,947,436 21,769,090
Funds held in trust for construction
of new facility..................... 680,372 710,929 729,087
OTHER ASSETS........................... 1,220,297 2,668,592 3,024,794
COST IN EXCESS OF NET ASSETS OF
BUSINESS ACQUIRED...................... -0- 1,847,905 1,769,271
----------- ----------- -----------
$58,917,220 $78,038,570 $83,951,509
=========== =========== ===========
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable..................... $ 3,086,776 $ 4,858,554 $ 3,974,185
Accrued compensation and related
expenses............................ 3,055,420 3,827,187 2,932,812
Accrued expenses..................... 1,968,977 2,694,298 3,479,913
Income taxes......................... 658,364 1,572,121 1,633,650
Current portion of long-term
obligations......................... 404,866 498,150 492,729
----------- ----------- -----------
TOTAL CURRENT LIABILITIES........ 9,174,403 13,450,310 12,513,289
LONG-TERM OBLIGATIONS.................. 4,854,440 5,537,996 5,241,953
MINORITY INTEREST...................... 664,268 681,068 646,199
COMMITMENTS
SHAREHOLDERS' EQUITY
Common Stock, $.01 par value;
authorized 40,000,000 shares;
issued and outstanding
16,344,690 shares at June 30, 1994,
16,744,785 shares at June 30, 1995,
and 16,851,860 shares at
December 31, 1995.................. 163,446 167,448 168,519
Additional capital................... 16,790,919 19,254,977 19,706,538
Retained earnings.................... 27,269,744 38,946,771 45,675,011
----------- ----------- -----------
TOTAL SHAREHOLDERS' EQUITY....... 44,224,109 58,369,196 65,550,068
----------- ----------- -----------
$58,917,220 $78,038,570 $83,951,509
=========== =========== ===========
</TABLE>
See notes to consolidated financial statements.
F-3
<PAGE>
RESPIRONICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
<TABLE>
<CAPTION>
YEAR ENDED JUNE 30 SIX MONTHS ENDED DECEMBER 31
1993 1994 1995 1994 1995
----------- ----------- ----------- -------------- --------------
(UNAUDITED)
<S> <C> <C> <C> <C> <C>
Net sales............... $69,285,613 $78,171,028 $99,450,333 $ 45,537,612 $ 56,915,794
Cost of goods sold...... 32,113,280 34,830,308 43,077,158 19,659,362 24,895,319
----------- ----------- ----------- -------------- --------------
37,172,333 43,340,720 56,373,175 25,878,250 32,020,475
General and
administrative
expenses............... 10,580,602 10,027,842 14,050,071 6,811,820 7,847,827
Sales, marketing and
commission expenses.... 12,313,483 15,069,159 17,696,059 8,298,675 9,513,054
Research and development
expenses............... 3,555,903 4,794,242 7,077,216 3,060,328 4,061,333
Nonrecurring charges.... -0- 7,086,085 -0- -0- -0-
Interest expense........ 175,843 171,223 193,550 95,943 100,595
Other income............ (549,635) (624,180) (1,178,685) (509,783) (532,235)
----------- ----------- ----------- -------------- --------------
26,076,196 36,524,371 37,838,211 17,756,983 20,990,574
----------- ----------- ----------- -------------- --------------
INCOME BEFORE
INCOME TAXES...... 11,096,137 6,816,349 18,534,964 8,121,267 11,029,901
Income taxes............ 3,717,206 2,075,105 6,857,937 3,004,871 4,301,661
----------- ----------- ----------- -------------- --------------
NET INCOME........ $ 7,378,931 $ 4,741,244 $11,677,027 $ 5,116,396 $ 6,728,240
=========== =========== =========== ============== ==============
Earnings per Share...... $ 0.43 $ 0.27 $ 0.67 $ 0.29 $ 0.38
=========== =========== =========== ============== ==============
Weighted Average Number
of Shares Used in
Computing Earnings Per
Share.................. 17,318,606 17,280,680 17,532,422 17,346,028 17,730,325
</TABLE>
See notes to consolidated financial statements.
F-4
<PAGE>
RESPIRONICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
<TABLE>
<CAPTION>
SIX MONTHS ENDED
YEAR ENDED JUNE 30 DECEMBER 31
1993 1994 1995 1994 1995
----------- ----------- ----------- ----------- ----------
(UNAUDITED)
<S> <C> <C> <C> <C> <C>
OPERATING ACTIVITIES
Net income.................. $ 7,378,931 $ 4,741,244 $11,677,027 $ 5,116,396 $6,728,240
Adjustments to
reconcile net income to
net cash provided by
operating activities:
Depreciation and
amortization............. 3,858,339 3,571,500 3,831,793 1,956,623 1,842,997
Provision for
deferred income taxes.... (1,390,181) 191,763 (178,819) -0- -0-
Provision for losses
on write-off of
equipment................ -0- 270,791 -0- -0- -0-
Provision for losses
on accounts
receivable............... 100,000 75,000 175,000 75,000 150,000
Loss on sale of
equipment................ -0- -0- 35,719 -0- -0-
Provision for
nonrecurring charges..... -0- 5,120,000 -0- -0- -0-
Changes in operating
assets and
liabilities:
Increase in
accounts receivable.... (2,198,685) (3,812,916) (4,515,077) (2,793,514) (5,727,886)
(Increase) decrease in
refundable income
taxes.................. -0- (1,787,265) 1,787,265 1,787,265 -0-
Increase in
inventories and prepaid
expenses............... (705,007) (1,057,575) (5,770,417) (2,387,016) (4,551,669)
Decrease (increase) in
other assets........... 289,908 (949,001) (1,448,295) (73,948) (356,202)
Increase (decrease) in
accounts payable....... 1,547,383 (738,842) 1,680,521 (765,318) (884,369)
Increase (decrease) in
accrued compensation
and related expenses... 1,642,235 (947,563) 764,557 (36,256) (894,375)
(Decrease) increase in
accrued expenses....... (42,716) 528,074 516,442 447,217 785,615
Increase (decrease) in
accrued income taxes... 188,668 (636,912) 912,999 (31,624) 61,529
----------- ----------- ----------- ----------- ----------
NET CASH PROVIDED
(USED) BY
OPERATING
ACTIVITIES.............. 10,668,875 4,568,298 9,468,715 3,294,825 (2,846,120)
INVESTING ACTIVITIES
Purchase of property,
plant and equipment........ (6,362,511) (7,734,854) (6,940,667) (2,961,843) (3,586,017)
Proceeds from sale of
equipment.................. -0- -0- 5,503 -0- -0-
Increase in funds held
in trust for
construction of new
facility................... -0- (680,372) (30,557) (12,595) (18,158)
Acquisition of a
business, net of cash
acquired................... -0- -0- (745,433) -0- -0-
----------- ----------- ----------- ----------- ----------
NET CASH USED BY
INVESTING
ACTIVITIES.............. (6,362,511) (8,415,226) (7,711,154) (2,974,438) (3,604,175)
FINANCING ACTIVITIES
Proceeds from long-
term obligations........... -0- 978,396 1,132,760 -0- -0-
Reduction in long-term
obligations................ (263,601) (382,508) (355,920) (233,028) (301,464)
Issuance of common
stock...................... 377,962 335,280 1,191,649 400,305 452,632
Increase (decrease) in
minority interest.......... -0- 664,268 16,800 4,601 (34,869)
----------- ----------- ----------- ----------- ----------
NET CASH PROVIDED
BY FINANCING
ACTIVITIES.............. 114,361 1,595,436 1,985,289 171,878 116,299
----------- ----------- ----------- ----------- ----------
INCREASE (DECREASE) IN
CASH AND SHORT-TERM
INVESTMENTS............. 4,420,725 (2,251,492) 3,742,850 492,265 (6,333,996)
Cash and short-term
investments at beginning
of period.................... 10,214,821 14,635,546 12,384,054 12,384,054 16,126,904
----------- ----------- ----------- ----------- ----------
CASH AND SHORT-TERM
INVESTMENTS AT END
OF PERIOD..................... $14,635,546 $12,384,054 $16,126,904 $12,876,319 $9,792,908
=========== =========== =========== =========== ==========
</TABLE>
See notes to consolidated financial statements.
F-5
<PAGE>
RESPIRONICS, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
<TABLE>
<CAPTION>
COMMON STOCK
-------------------
ADDITIONAL RETAINED
SHARES AMOUNT CAPITAL EARNINGS TOTAL
---------- -------- ----------- ----------- -----------
<S> <C> <C> <C> <C> <C>
Balance at July 1, 1992
as previously reported. 8,065,907 $ 80,659 $16,160,464 $15,149,569 $31,390,692
Two-for-one stock split. 8,065,907 80,659 (80,659) -0- -0-
---------- -------- ----------- ----------- -----------
BALANCE AT JULY 1,
1992 AS ADJUSTED...... 16,131,814 161,318 16,079,805 15,149,569 31,390,692
Net income for the year
ended June 30, 1993.... -0- -0- -0- 7,378,931 7,378,931
Shares sold pursuant to
stock option plans..... 89,346 894 343,668 -0- 344,562
Shares sold pursuant to
consulting agreement.. 8,000 80 33,320 -0- 33,400
---------- -------- ----------- ----------- -----------
BALANCE AT JUNE 30,
1993.................. 16,229,160 162,292 16,456,793 22,528,500 39,147,585
Net income for the year
ended June 30, 1994.... -0- -0- -0- 4,741,244 4,741,244
Shares sold pursuant to
stock option plans..... 107,530 1,074 289,526 -0- 290,600
Shares sold pursuant to
consulting agreement... 8,000 80 44,600 -0- 44,680
---------- -------- ----------- ----------- -----------
BALANCE AT JUNE 30,
1994.................. 16,344,690 163,446 16,790,919 27,269,744 44,224,109
Net income for the year
ended June 30, 1995.... -0- -0- -0- 11,677,027 11,677,027
Shares sold pursuant to
stock option plans..... 315,001 3,150 1,188,499 -0- 1,191,649
Acquisition of a
business............... 85,094 852 1,275,559 -0- 1,276,411
---------- -------- ----------- ----------- -----------
BALANCE AT JUNE 30,
1995.................. 16,744,785 167,448 19,254,977 38,946,771 58,369,196
Net income for the six
months ended December
31, 1995 (unaudited)... -0- -0- -0- 6,728,240 6,728,240
Shares sold pursuant to
stock option plans
(unaudited)............. 107,075 1,071 451,561 -0- 452,632
---------- -------- ----------- ----------- -----------
BALANCE AT DECEMBER
31, 1995 (unaudited).. 16,851,860 $168,519 $19,706,538 $45,675,011 $65,550,068
========== ======== =========== =========== ===========
</TABLE>
See notes to consolidated financial statements.
F-6
<PAGE>
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
RESPIRONICS, INC. AND SUBSIDIARIES
(INFORMATION PERTAINING TO THE SIX MONTH PERIODS ENDED DECEMBER 31, 1994 AND
1995 IS UNAUDITED.)
NOTE A--SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation: The consolidated financial statements include
the accounts of Respironics, Inc. (the Company), its consolidated wholly owned
foreign subsidiary, Respironics (HK) Ltd., its wholly owned domestic
subsidiary, RIC Investments, Inc., and a foreign joint venture in which it
holds a 51% equity investment. The joint venture partner's 49% equity interest
is included in the Company's financial statements as minority interest. All
significant intercompany accounts and transactions have been eliminated in
consolidation.
Revenue Recognition: Revenue is recognized from sales when a product is
shipped.
Inventories: Inventories are valued at the lower of cost (first-in, first-
out) or market.
Property, Plant and Equipment: Property, plant and equipment is recorded on
the basis of cost. Depreciation is computed using the straight-line method
based upon the estimated useful lives of the respective assets, except for
assets under capital leases which are depreciated using the straight-line
method over the shorter of the lease term or the estimated useful lives of
such assets. Amortization of assets under capital leases is included in
depreciation expense.
Income Taxes: Effective July 1, 1993, the Company adopted Statement of
Financial Accounting Standards #109, "Accounting for Income Taxes". Under this
method, deferred tax assets and liabilities are determined based on
differences between financial reporting and tax bases of assets and
liabilities and are measured using the enacted tax rates and laws that will be
in effect when differences are expected to reverse. The Company has elected
not to restate the consolidated financial statements of any prior years. The
cumulative effect of the adoption and the effect of the adoption on the
results of operations for the year ended June 30, 1994 were not material.
The Company does not provide for federal income taxes on the undistributed
earnings of its foreign subsidiary (other than deemed dividends which are
taxed currently) because such earnings are reinvested and, in the opinion of
management, will continue to be reinvested indefinitely.
Foreign Currency Translation: The Company follows Statement of Financial
Accounting Standards No. 52 for the translation of the accounts of its foreign
subsidiary, Respironics (HK) Ltd., and its joint venture. Foreign currency
assets and liabilities are translated into United States dollars at the rate
of exchange existing at the statement date or historical rates depending upon
the nature of the account. Income and expense amounts are translated at the
average of the monthly exchange rates. Adjustments resulting from these
translations are immaterial.
Stock Split: In February 1995, the Company's Board of Directors declared a
two-for-one stock split of the Company's common stock, distributing on March
17, 1995 one additional share of common stock for each share held of record on
March 3, 1995. All agreements concerning stock options were amended to provide
for issuance of two shares of common stock for every one share issuable prior
to the split. An amount equal to the par value of the shares issued was
transferred from additional capital to the common stock account. This transfer
has been reflected in the consolidated statements of changes in shareholders'
equity at July 1, 1992. All references to number of shares, except shares
authorized, and to per-share information in the consolidated financial
statements have been adjusted to reflect the stock split on a retroactive
basis.
Stock Options: Stock options are granted to certain employees and certain
members of the Company's Board of Directors at fair market value on the date
of the grant. Proceeds from the exercise of common stock options are credited
to shareholders' equity at the date the options are exercised. There are no
charges or credits to income with respect to these options.
F-7
<PAGE>
Earnings per Share: Earnings per share is based on the weighted average
number of shares outstanding during each year and the assumed exercise of
dilutive stock options (less the number of treasury shares assumed to be
purchased with the proceeds using the average market price of the Company's
common stock for primary earnings per share and the higher of the ending
market price or average market price for fully diluted earnings per share).
Cash and Short-Term Investments: The Company considers all highly liquid
investments with a maturity of 90 days or less when purchased to be cash and
short-term investments.
Capitalized Software Development Costs: In 1994, the Company commenced
development of software to be included in certain of its new products.
Software development costs have been capitalized and will be amortized to the
cost of product revenues over the estimated economic lives of the products
that will include such software. The products that include such software are
expected to be introduced for sale during the year ending June 30, 1996. Total
capitalized software development costs were $675,000, $1,982,000 and
$2,552,000 at June 30, 1994, June 30, 1995, and December 31, 1995,
respectively.
NOTE B--SHORT-TERM INVESTMENTS
Short-term investments consist primarily of money market accounts and
certificates of deposit issued by large commercial banks located in the United
States and Hong Kong. These investments are readily convertible to cash and
are stated at cost which approximates market.
NOTE C--INVENTORIES
Inventories consisted of the following:
<TABLE>
<CAPTION>
JUNE 30 DECEMBER 31
1994 1995 1995
---------- ----------- -----------
(UNAUDITED)
<S> <C> <C> <C>
Raw materials............................. $5,268,039 $ 7,960,573 $12,821,590
Work-in-process........................... 818,400 1,105,010 1,496,414
Finished goods............................ 1,747,316 4,071,081 2,982,718
---------- ----------- -----------
$7,833,755 $13,136,664 $17,300,722
========== =========== ===========
</TABLE>
F-8
<PAGE>
NOTE D--LONG TERM OBLIGATIONS
Long-term obligations consisted of:
<TABLE>
<CAPTION>
JUNE 30 DECEMBER 31
1994 1995 1995
---------- ---------- -----------
(UNAUDITED)
<S> <C> <C> <C>
1989 Economic Development Revenue Bonds,
variable interest rate (effective rate
of 6.38%, including letter of credit and
remarketing fees, at December 31, 1995),
principal payable in annual installments
of $100,000 through 1996 and $200,000
thereafter through 2004................. $2,000,000 $1,900,000 $1,800,000
Industrial Development Authority Loan,
payable in monthly installments of
$13,777, including interest at 3%,
through June 2005....................... 1,528,469 1,407,312 1,345,358
Redevelopment Authority Loan, payable in
quarterly installments of $14,533,
including interest at 5%, through June
2005.................................... 514,172 481,137 463,994
Capital lease obligation, payable in
quarterly installments of $19,834
including interest at a floating rate
(2.25% at December 31, 1995) through
June 1997............................... 201,353 131,581 95,245
Redevelopment Authority Loan, payable in
monthly installments of $6,296,
including interest at 2%, through July
2009.................................... 978,395 921,894 893,217
Capital lease obligation, payable in
monthly installments of $1,860,
including interest at 4.60%, through
January 1996............................ 36,917 13,889 2,005
Industrial Development Authority Loan,
payable in monthly installments of
$7,289, including interest at 2%,
through March 2010...................... -0- 1,132,240 1,099,487
Capital lease obligation, payable in
monthly installments of $2,284,
including interest at 4.62%, through
April 1997.............................. -0- 48,093 35,376
---------- ---------- ----------
5,259,306 6,036,146 5,734,682
Less current portion..................... 404,866 498,150 492,729
---------- ---------- ----------
$4,854,440 $5,537,996 $5,241,953
========== ========== ==========
</TABLE>
The Economic Development Revenue Bonds, the Industrial Development Authority
Loans, and the Redevelopment Authority Loans are secured by mortgages upon the
Company's headquarters and manufacturing facility in Murrysville,
Pennsylvania. Proceeds from the bonds and the loans were used to finance the
construction and expansion of the facility. The Company is required to meet
certain financial covenants in connection with these obligations, including
those relating to current ratio, ratio of total liabilities to tangible net
worth, and minimum tangible net worth. At June 30, 1994, June 30, 1995 and
December 31, 1995 the Company was in compliance with these covenants.
The Company is a party to capital lease agreements with commercial banks
relating to certain of its fixed assets. The lease terms are two to four years
with options for the Company to purchase the assets at the end of the lease.
Assets under capital leases at June 30, 1995 and December 31, 1995 consist of
machinery and equipment and office equipment with a net book value of $149,228
and $94,863, respectively. Capital lease obligations incurred are considered
non-cash items and, accordingly, are not
F-9
<PAGE>
considered in the consolidated statements of cash flows. Capital lease
obligations incurred were $52,265 for the year ended June 30, 1995, and there
were none incurred for the six month period ended December 31, 1995.
The Company also has $1,250,000 available under a line of credit facility
with a commercial bank at the bank's prime rate until the expiration date of
October 31, 1996. Borrowings made on this line of credit are unsecured. The
Company is required to meet certain financial covenants under this line of
credit relating to current ratio, the ratio of total liabilities to tangible
net worth and a minimum tangible net worth. There were no outstanding
borrowings under this credit facility.
Scheduled maturities of long-term obligations for the six months ended June
30, 1996 and the next five years are as follows:
<TABLE>
<CAPTION>
MATURITIES OF MINIMUM LEASE INTEREST ON
LONG- PAYMENTS UNDER CAPITAL
TERM DEBT CAPITAL LEASES LEASES TOTAL
------------- -------------- ----------- ----------
<S> <C> <C> <C> <C>
Six months ended June
30, 1996................ $ 143,193 $ 55,381 $(3,043) $ 195,531
1997.................... 492,623 82,343 (2,055) 572,911
1998.................... 500,847 -0- -0- 500,847
1999.................... 509,516 -0- -0- 509,516
2000.................... 518,370 -0- -0- 518,370
2001.................... 527,507 -0- -0- 527,507
Thereafter.............. 2,910,000 -0- -0- 2,910,000
---------- -------- ------- ----------
Total................... $5,602,056 $137,724 $(5,098) $5,734,682
========== ======== ======= ==========
</TABLE>
Interest paid was $180,421, $167,718 and $194,220 for the years ended June
30, 1993, 1994, and 1995, respectively and was $93,790 and $100,892 for the
six months ended December 31, 1994 and 1995, respectively.
NOTE E--INCOME TAXES
<TABLE>
<CAPTION>
YEAR ENDED JUNE 30
1993 1994 1995
----------- ---------- ----------
<S> <C> <C> <C>
Income taxes consisted of:
Current:
Federal................................ $ 3,988,590 $1,509,015 $5,379,275
Foreign................................ 94,746 60,112 197,943
State.................................. 1,024,051 314,214 1,459,538
----------- ---------- ----------
5,107,387 1,883,341 7,036,756
Deferred:
Federal................................ (1,071,993) 151,826 (165,132)
State.................................. (318,188) 39,938 (13,687)
----------- ---------- ----------
(1,390,181) 191,764 (178,819)
----------- ---------- ----------
TOTAL INCOME TAXES..................... $ 3,717,206 $2,075,105 $6,857,937
=========== ========== ==========
</TABLE>
F-10
<PAGE>
The difference between the statutory U.S. federal income tax rate and the
Company's effective income tax rate is explained below:
<TABLE>
<CAPTION>
YEAR ENDED JUNE 30
1993 1994 1995
------ ------ ------
<S> <C> <C> <C>
Statutory federal income tax rate.................. 34% 34% 35%
Increases (decreases):
State taxes...................................... 4 3 5
Tax credits utilized............................. (3) (7) (3)
Tax on foreign earnings at less than the
statutory rate.................................. (5) (5) -0-
Other items, net, none of which individually
exceeds 5% of federal income taxes at
statutory rates................................. 3 5 -0-
------ ------ ------
EFFECTIVE INCOME TAX RATE....................... 33% 30% 37%
====== ====== ======
</TABLE>
Deferred income tax assets consisted of the following:
<TABLE>
<CAPTION>
JUNE 30
1994 1995
---------- ----------
<S> <C> <C>
Deferred compensation............................... $ 204,546 $ -0-
Inventories......................................... 418,607 600,513
Allowance for bad debts............................. 210,720 245,804
Depreciation........................................ 617,944 635,128
Accruals............................................ 555,645 673,926
Other............................................... 14,314 45,224
---------- ----------
Total............................................... $2,021,776 $2,200,595
========== ==========
</TABLE>
Income before income taxes consisted of the following:
<TABLE>
<CAPTION>
YEAR ENDED JUNE 30
1993 1994 1995
----------- ---------- -----------
<S> <C> <C> <C>
United States........................... $ 9,038,558 $5,578,476 $17,935,537
Foreign................................. 2,057,579 1,237,873 599,427
----------- ---------- -----------
Total................................... $11,096,137 $6,816,349 $18,534,964
=========== ========== ===========
</TABLE>
Undistributed earnings of the foreign subsidiary on which no U.S. income tax
has been provided amounted to $9,537,838 at June 30, 1995.
The Company's operation in the Peoples Republic of China is affected by an
income tax holiday. Net income increased by $568,955 ($0.03 per share),
$345,564 ($0.02 per share), and $339,851 ($0.02 per share) for the years ended
June 30, 1993, 1994, and 1995 respectively, as a result of this income tax
holiday. Under the terms of the income tax holiday, the Company's operation in
the Peoples Republic of China paid no income tax for the years ended June 30,
1993 and 1994. The income tax rate increased to 7.5% for the year ended June
30, 1995 and will remain at 7.5% for years ending June 30, 1996 and 1997 and
will then increase to 15% for years thereafter. The applicable statutory
income tax rate in the Peoples Republic of China is approximately 33%.
Income taxes paid were $4,918,719, $4,620,928, and $4,335,733 for the years
ended June 30, 1993, 1994, and 1995, respectively and were $3,036,495 and
$4,240,132 for the six months ended December 31, 1994 and 1995, respectively.
F-11
<PAGE>
NOTE F--STOCK OPTION PLANS
The Company has the 1984 Incentive Stock Option Plan (the "1984 Plan") which
provided options to eligible employees to purchase common stock over five or
ten years at fair market value at the time of the grant. Options become
exercisable one year from the date of the grant at a rate not exceeding 25%
per year (subject to possible acceleration in certain circumstances). The
Company reserved shares of its common stock and authorized options to purchase
3,400,000 shares of common stock under the 1984 Plan. The 1984 Plan terminated
as to new grants on December 31, 1993.
Pertinent information regarding options under the 1984 Plan follows:
<TABLE>
<CAPTION>
OPTION SHARES
-------------------------------------------------
SIX MONTHS ENDED
YEAR ENDED JUNE 30 DECEMBER 31
1993 1994 1995 1995
--------- --------- --------- ----------------
(UNAUDITED)
<S> <C> <C> <C> <C>
Outstanding at beginning
of period................ 1,330,562 1,277,860 1,298,466 929,314
Granted:
$ 8.25 per share........ 5,000 -0- -0- -0-
$ 8.32 per share........ -0- 2,000 -0- -0-
$ 9.25 per share........ -0- 132,000 -0- -0-
$10.07 per share........ 104,362 -0- -0- -0-
$10.38 per share........ 1,000 -0- -0- -0-
Exercised:
$ 1.00 per share........ (12,400) (10,100) (2,000) (400)
$ 1.38 per share........ (6,400) (46,600) (80,000) (2,000)
$ 2.82 per share........ (9,800) (11,800) (18,300) (2,956)
$ 4.50 per share........ (48,920) (34,610) (187,250) (77,972)
$ 5.41 per share........ -0- -0- (600) -0-
$ 6.22 per share........ (11,426) (4,420) (20,696) (6,787)
$ 8.32 per share........ -0- -0- -0- (500)
$10.07 per share........ -0- -0- (1,580) (1,600)
Canceled................. (74,118) (5,864) (58,726) (2,100)
--------- --------- --------- -------
Outstanding at end of
period................... 1,277,860 1,298,466 929,314 834,999
========= ========= ========= =======
Exercisable at end of
period................... 911,866 802,758 749,134 738,354
========= ========= ========= =======
Shares available for
future grant............. 191,236 -0- -0- -0-
========= ========= ========= =======
</TABLE>
The Company also has the 1992 Stock Incentive Plan (the "1992 Plan") which
was approved by the Company's shareholders in November 1992. Under the 1992
Plan, eligible employees may receive options to purchase common stock over ten
years at option prices that may not be less than fair market value at the date
of grant. Stock options granted under the 1992 Plan become exercisable no
sooner than six months from grant date (subject to possible acceleration under
certain circumstances) and such options may include cash payment rights.
Eligible employees may also receive awards of restricted shares of the
Company's common stock under the 1992 Plan. The aggregate number of options
and restricted shares which may be issued under the 1992 Plan is 1,000,000.
Options to purchase 106,960 shares at $9.88 per share were granted during the
year ended June 30, 1994 and options to purchase 52,752 shares at $16.25 per
share and 5,000 shares at $13.38 per share were granted during the year ended
June 30, 1995. Options to purchase 2,575 shares at $9.88 per share were
exercised during the year ended June 30, 1995. Options to purchase 60 shares
at $9.88 per share were exercised during the six months ended December 31,
1995. Options to purchase 5,050 shares were canceled during the year ended
June 30, 1995. Options to
F-12
<PAGE>
purchase 1,000 shares were cancelled during the six months ended December 31,
1995. At June 30, 1995, total options to purchase 157,087 shares were
outstanding under the 1992 Plan, of which 23,628 were exercisable. At December
31, 1995, total options to purchase 156,027 shares were outstanding under the
1992 Plan, of which 25,019 were exercisable.
In connection with an initial public offering that was completed in June
1988, an officer of the Company exchanged his rights in certain non-patented
products for an option to purchase 400,000 shares of common stock at a price
of $1.88 per share. The option to purchase 80,000 of the shares was
exercisable immediately, and options to purchase 80,000 shares became
exercisable on each of June 30, 1989, 1990, 1991, and 1992. The option will be
exercisable for a maximum period of ten years after grant. Options to purchase
15,000 shares were exercised during the six months ended December 31, 1995.
In November 1991, the Company's shareholders approved the adoption of the
1991 Non-Employee Directors' Stock Option Plan (the "Directors' Plan"). The
aggregate number of shares which may be issued and as to which grants of
options may be made under the Directors' Plan is 200,000. All options under
the Directors' Plan are granted to members of the Company's Board of Directors
who are not employees of the Company. Such options are granted at fair market
value on the date of grant.
Under the provisions of the Directors' Plan, in November 1991 each of the
four non-employee directors who had been non-employee directors for at least
two years prior to the approval of the Directors' Plan received a one-time
option to purchase 10,000 shares at an option price of $6.13 per share. In
addition, each of the five non-employee directors (regardless of years of
service) received an option to purchase 5,100 shares at an option price of
$6.13 per share. In November 1992, each non-employee director received an
option to purchase 5,100 shares at an option price of $10.63 per share. In
November 1993, each non-employee director received an option to purchase 5,100
shares at an option price of $9.50 per share. In November 1994, each non-
employee director received an option to purchase 5,100 shares at an option
price of $11.25 per share. In November 1995, each non-employee director
received an option to purchase 5,100 shares at $19.69 per share. In the
future, each non-employee director will receive an option to purchase an
additional 5,100 shares on the third business day following the Company's
annual meeting of shareholders. These grants will continue until options for
all the share available under the Directors' Plan have been granted.
The one time option granted to non-employee directors with more than two
years of service was exercisable in full three months after the date of grant.
For all other options granted under the Directors' Plan, 25% of the shares are
exercisable one year after the date of the grant, 25% are exercisable two
years after the date of grant, and the remaining 50% are exercisable three
years after the date of grant. All options granted under the Directors' Plan
expire ten years after the date of grant. Options to purchase 2,000 shares at
$6.13 per share were exercised during the year ended June 30, 1995.
F-13
<PAGE>
NOTE G--FINANCIAL INFORMATION BY GEOGRAPHIC AREAS AND MAJOR CUSTOMERS
<TABLE>
<CAPTION>
SIX MONTHS ENDED
YEAR ENDED JUNE 30 DECEMBER 31
1993 1994 1995 1994 1995
------------ ----------- ----------- ----------- -----------
(UNAUDITED)
<S> <C> <C> <C> <C> <C>
NET SALES
Hong Kong:
Unaffiliated
customers............ $ 1,157,402 $ 1,462,292 $ 1,720,248 $ 983,886 $ 1,114,715
Interarea transfers... 9,281,661 7,312,399 8,430,823 3,945,241 4,112,123
------------ ----------- ----------- ----------- -----------
10,439,063 8,774,691 10,151,071 4,929,127 5,226,838
United States:
Unaffiliated
customers............ 68,128,211 76,708,736 97,730,086 44,553,726 55,801,079
Interarea transfers... 794,124 543,883 750,744 642,446 311,631
------------ ----------- ----------- ----------- -----------
68,922,335 77,252,619 98,480,830 45,196,172 56,112,710
Eliminations--
transfers............ (10,075,785) (7,856,282) (9,181,568) (4,587,687) (4,423,754)
------------ ----------- ----------- ----------- -----------
Net Sales.............. $ 69,285,613 $78,171,028 $99,450,333 $45,537,612 $56,915,794
============ =========== =========== =========== ===========
OPERATING PROFIT
Hong Kong.............. $ 2,359,200 $ 1,538,966 $ 877,325 $ 649,632 $ 431,162
United States.......... 12,411,549 9,315,357 22,239,437 9,416,007 13,363,737
------------ ----------- ----------- ----------- -----------
Operating Profit........ 14,770,749 10,854,323 23,116,762 10,065,639 13,794,899
Corporate expense...... 3,498,769 3,866,751 4,388,248 1,848,429 2,664,403
Interest expense....... 175,843 171,223 193,550 95,943 100,595
------------ ----------- ----------- ----------- -----------
Income Before Income
Taxes.................. $ 11,096,137 $ 6,816,349 $18,534,964 $ 8,121,267 $11,029,901
============ =========== =========== =========== ===========
</TABLE>
Interarea transfers are accounted for at prices comparable to unaffiliated
customer sales reduced by an approximation of costs not incurred on internal
sales.
The Company sells to distributors in the health care industry and closely
monitors the extension of credit to both domestic and foreign customers,
including obtaining and analyzing credit applications for all new accounts and
maintaining an active program to contact customers promptly when invoices
become past due. Sales to one customer accounting for 10% or more of net sales
were $6,711,000 for the year ended June 30, 1993. Sales to another customer
(accounting for 10% or more of net sales) were $8,569,000 for the year ended
June 30, 1994 and $10,955,000 for the year ended June 30, 1995. Sales to the
same customer (which merged with another customer in August 1995) were
$5,160,000 and $9,595,000 for the six months ended December 31, 1994 and 1995.
F-14
<PAGE>
Additional information regarding assets and liabilities by geographic area
follows:
<TABLE>
<CAPTION>
JUNE 30 DECEMBER 31
1994 1995 1995
----------- ----------- -----------
(UNAUDITED)
<S> <C> <C> <C>
IDENTIFIABLE ASSETS
Hong Kong.............................. $ 3,773,038 $ 5,597,154 $ 6,591,846
United States.......................... 40,738,352 54,113,917 65,366,160
----------- ----------- -----------
44,511,390 59,711,071 71,958,006
Corporate assets (primarily cash and
short-term investments).............. 14,405,830 18,327,499 11,993,503
----------- ----------- -----------
Total Assets.......................... $58,917,220 $78,038,570 $83,951,509
=========== =========== ===========
TOTAL ASSETS
Hong Kong.............................. $ 9,328,819 $11,140,130 $11,497,391
United States.......................... 49,588,401 66,898,440 72,454,118
----------- ----------- -----------
$58,917,220 $78,038,570 $83,951,509
=========== =========== ===========
TOTAL LIABILITIES
Hong Kong.............................. $ 1,548,270 $ 2,712,833 $ 2,905,218
United States.......................... 13,144,841 16,956,541 15,496,223
----------- ----------- -----------
$14,693,111 $19,669,374 $18,401,441
=========== =========== ===========
</TABLE>
NOTE H--RETIREMENT PLAN
The Company has a Retirement Savings Plan which is available to all United
States employees. Employees may contribute up to 15% (to a defined maximum) of
their compensation. The Company matches employee contributions (up to 3% of
each employee's compensation) at a 100% rate and may make discretionary
contributions. The Company contributed $169,000, $357,000 and $420,000 to the
plan for the years ended June 30, 1993, 1994, and 1995, respectively and
$191,000 and $292,000 for the six months ended December 31, 1994 and 1995.
The Company's current benefit program does not provide postretirement
benefits to employees.
NOTE I--DISTRIBUTION AGREEMENT
In June 1991, the Company entered into a distribution agreement with the
owner of a non-invasive ventilator product. Under the terms of the agreement,
the Company had the exclusive United States distribution rights for a product
that was to be produced by the manufacturer. The initial term of the agreement
was three years with provisions to extend the term for additional periods. A
six-month extension of the initial term expired December 31, 1994. As part of
the agreement, the Company paid $5,000,000 to the manufacturer, representing a
partial prepayment for the product to be sold by the Company during the
initial term of the agreement.
Because of the manufacturer's repeated failures to meet stipulated
requirements, particularly in assuring compliance with Good Manufacturing
Practice as required by FDA law and regulations, and the Company's resulting
inability to introduce the product for sale, in June 1994 the Company
concluded that the ultimate realizability of the prepayment was no longer
probable. Accordingly, during the quarter ended June 30, 1994, the Company
recorded nonrecurring charges totaling $5,120,000 to write off the remaining
balance on the prepayment and the net book value of units that had been
purchased.
F-15
<PAGE>
NOTE J--DISCONTINUANCE OF PRODUCT LINE
In November 1993, the Company discontinued the production and sale of its
BagEasy line of disposable manual resuscitators and recalled all remaining
BagEasy products in distribution channels and customer inventories.
Accordingly, during the quarter ended September 30, 1993, the Company recorded
nonrecurring charges of $1,966,000 which included provisions for write-offs of
inventories and fixed assets, the satisfaction of purchase order and
compensation commitments, and costs associated with the recall.
NOTE K--JOINT VENTURE
During the quarter ended December 31, 1993, the Company completed a 51%
equity investment, totaling approximately $600,000, in a joint venture with a
company located in the Peoples Republic of China. The Company believes that
this joint venture will facilitate the wider distribution of the Company's
products in the Peoples Republic of China and will also manufacture and
distribute medical products and over-the-counter medicines in that country.
The joint venture is not expected to be fully operational until the second
half of fiscal year 1996.
NOTE L--ACQUISITION
On April 6, 1995, the Company acquired Vitalog Monitoring, Inc., a
California company that designs, manufactures and markets sleep monitoring and
diagnostic equipment. This combination was treated for financial reporting
purposes as a purchase. Vitalog's results of operations have been included in
the Company's consolidated financial statements beginning April 7, 1995.
Vitalog's operations were not material in relation to the Company's
consolidated financial statements and pro forma financial information has
therefore not been presented.
Consideration paid was $745,000 in cash (including transactions costs) and
85,094 shares of the Company's common stock valued at $1,276,000 in exchange
for the outstanding stock of Vitalog, related patents, and non-competition
agreements. The cost in excess of net assets acquired was $1,887,000 and is
being amortized on a straight line basis over 12 years.
NOTE M--CONTINGENCY
The Company is a party to an action filed in a federal District Court in
January 1995 in which a competitor alleges that the Company's sale in the
United States of certain products infringes three of the competitor's patents.
In its response to the action, the Company has denied the allegations and has
separately sought a declaratory judgment that the claims under the patents are
invalid and that the Company does not infringe upon the patents. Discovery in
the case is continuing. The Company believes that none of its products
infringe any of the patents in question in the event that any one or more of
such patents should be held to be valid and enforceable, and it intends to
vigorously defend this position.
F-16
<PAGE>
NOTE N--QUARTERLY RESULTS OF OPERATIONS (UNAUDITED)
Following are the unaudited quarterly results of operations for the fiscal
years ended June 30, 1994, 1995 and 1996:
<TABLE>
<CAPTION>
1994
------------------------------------------------
THREE MONTHS ENDED
SEPTEMBER 30 DECEMBER 31 MARCH 31 JUNE 30
------------ ----------- ----------- -----------
<S> <C> <C> <C> <C>
Net Sales................. $18,224,518 $18,600,037 $19,307,611 $22,038,862
Gross Profit.............. 9,989,061 10,099,895 10,704,488 12,547,276
Nonrecurring Charges...... 1,966,085 -0- -0- 5,120,000
Net Income (Loss)......... 873,481 2,063,884 2,244,295 (440,416)
Earnings (Loss) Per Share. $ 0.05 $ 0.12 $ 0.13 $ (0.03)
<CAPTION>
1995
------------------------------------------------
THREE MONTHS ENDED
SEPTEMBER 30 DECEMBER 31 MARCH 31 JUNE 30
------------ ----------- ----------- -----------
<S> <C> <C> <C> <C>
Net Sales................. $21,669,809 $23,867,803 $25,599,736 $28,312,985
Gross Profit.............. 12,199,078 13,679,172 14,485,883 16,009,042
Net Income................ 2,420,016 2,696,380 3,071,740 3,488,891
Earnings Per Share........ $ 0.14 $ 0.15 $ 0.17 $ 0.20
<CAPTION>
1996
------------------------------------------------
THREE MONTHS ENDED
SEPTEMBER 30 DECEMBER 31 MARCH 31 JUNE 30
------------ ----------- ----------- -----------
<S> <C> <C> <C> <C>
Net Sales................. $26,674,675 $30,241,119 -- --
Gross Profit.............. 15,160,165 16,860,310 -- --
Net Income................ 3,219,272 3,508,968 -- --
Earnings Per Share........ $ 0.18 $ 0.20 -- --
</TABLE>
F-17
<PAGE>
================================================================================
NO PERSON HAS BEEN AUTHORIZED IN CONNECTION WITH THE OFFERING MADE HEREBY TO
GIVE ANY INFORMATION OR TO MAKE ANY REPRESENTATION NOT CONTAINED IN THIS
PROSPECTUS AND, IF GIVEN OR MADE, SUCH INFORMATION OR REPRESENTATION MUST NOT
BE RELIED UPON AS HAVING BEEN AUTHORIZED BY THE COMPANY, THE SELLING
STOCKHOLDERS OR ANY UNDERWRITER. THIS PROSPECTUS DOES NOT CONSTITUTE AN OFFER
TO SELL OR A SOLICITATION OF ANY OFFER TO BUY ANY OF THE SECURITIES OFFERED
HEREBY TO ANY PERSON OR BY ANYONE IN ANY JURISDICTION IN WHICH IT IS UNLAWFUL
TO MAKE SUCH OFFER OR SOLICITATION. NEITHER THE DELIVERY OF THIS PROSPECTUS NOR
ANY SALE MADE HEREUNDER SHALL, UNDER ANY CIRCUMSTANCES, CREATE ANY IMPLICATION
THAT THE INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY DATE SUBSEQUENT TO
THE DATE HEREOF.
------------
TABLE OF CONTENTS
Page
<TABLE>
<S> <C>
Available Information...................................................... 2
Additional Information..................................................... 2
Prospectus Summary......................................................... 3
Risk Factors............................................................... 6
Price Range of Common Stock................................................ 8
Use of Proceeds............................................................ 8
Dividend Policy............................................................ 8
Capitalization............................................................. 9
Selected Financial Data.................................................... 10
Management's Discussion and Analysis of Results of Operations and Financial
Condition................................................................. 11
Business................................................................... 18
Management................................................................. 33
Principal and Selling Stockholders......................................... 35
Underwriting............................................................... 37
Legal Matters.............................................................. 38
Experts.................................................................... 38
Incorporation of Certain Documents by Reference............................ 38
Index to Consolidated Financial Statements................................. F-1
</TABLE>
------------
================================================================================
================================================================================
3,030,000 Shares
[LOGO OF RESPIRONICS, INC.]
Common Stock
------------
PROSPECTUS
------------
Alex. Brown & Sons
INCORPORATED
Cowen & Company
Parker/Hunter INCORPORATED
March 25, 1996
================================================================================
